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Abstract 
Osteoarthritis causes debilitating pain and disability, resulting in a considerable 
socioeconomic burden, yet no drugs are available that prevent disease onset or progression. 
Here, we develop, validate and use rapid-throughput imaging techniques to identify abnormal 
joint phenotypes in randomly selected mutant mice generated by the International Knockout 
Mouse Consortium. We identify 14 genes with functional involvement in osteoarthritis 
pathogenesis, including the homeobox gene Pitx1, and functionally characterize 6 candidate 
human osteoarthritis genes in mouse models. We demonstrate sensitivity of the methods by 
identifying age-related degenerative joint damage in wild-type mice. Finally, we phenotype 
previously generated mutant mice with an osteoarthritis-associated polymorphism in the Dio2 
gene by CRISPR/Cas9 genome editing and demonstrate a protective role in disease onset 
with public health implications. This expanding resource of mutant mice will accelerate 
functional gene discovery in osteoarthritis and offer drug discovery opportunities for this 
common, incapacitating chronic disease.  
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Introduction 
Osteoarthritis is the commonest cause of joint destruction, pain and disability. Joint 
replacement for end-stage disease remains the only treatment, leading to an escalating 
healthcare crisis in our obese and ageing society. Osteoarthritis is a complex trait and the 86 
reported genome-wide associated loci explain only a small proportion of its heritability, which 
is estimated between 40-70%1, 2, 3. 
 
Osteoarthritis is characterized by articular cartilage damage and loss, together with structural 
abnormalities of subchondral bone and low-grade chronic joint inflammation. It is unknown 
which of these processes trigger disease or which represent secondary responses to joint 
destruction4. It is also uncertain whether the pathogenesis of osteoarthritis reflects an 
abnormal response to injury involving defective stem cell recruitment and abnormal cell 
proliferation, differentiation, metabolism, apoptosis and senescence5, 6. 
 
Chondrocytes in healthy articular cartilage are resistant to terminal differentiation whereas 
they revert to a developmental program following injury, in which they proliferate and undergo 
hypertrophic differentiation with accelerated cartilage mineralization7. Osteoarthritis 
pathogenesis involves cross-talk between the synovium, articular cartilage and subchondral 
bone8, although the timing of bone remodeling relative to cartilage degradation remains 
uncertain9. Nevertheless, increases in apoptotic and senescent chondrocytes are triggered by 
processes including endoplasmic reticulum stress10. Senescent cells express a secretory 
phenotype that contributes to inflammation, vascular invasion11 and cartilage breakdown via 
key pathways that stimulate matrix metalloproteases12 and aggrecan-specific proteinases13. 
 
Despite the profound clinical and socio-economic impacts of osteoarthritis, our understanding 
of its genetic basis is in its infancy. We hypothesize that accelerating gene discovery in 
osteoarthritis will increase understanding of joint physiology and disease pathogenesis and 
facilitate identification of drug targets that prevent or delay joint destruction. Studies of extreme 
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phenotypes in humans have underpinned identification of the molecular basis of single gene 
disorders and mechanisms of complex disease and resulted in new treatments14, 15. Analogous 
to our gene discovery studies in osteoporosis16, 17, 18, 19, 20, we propose that a joint-specific 
extreme phenotype screen in mutant mice will accelerate functional gene discovery in 
osteoarthritis. 
 
Mutant mice are generated at the Sanger Institute as part of the International Mouse 
Phenotyping Consortium (IMPC). Mice undergo broad phenotyping using the International 
Mouse Phenotyping Resource of Standardized Screen (IMPReSS) that is completed at 16 
weeks of age when tissues are harvested for further analysis. In the Origins of Bone and 
Cartilage Disease (OBCD) Project we collaborate with IMPC and receive knee joints for 
analysis. Rapid-throughput phenotyping of the mouse knee requires quantitative imaging; this 
presents a complex and unsolved challenge that relates to anatomical size, three-dimensional 
complexity, image resolution and the necessity to maintain joints in their native fully-hydrated 
state. 
 
Here we present the invention, optimization, validation and application of a rapid-throughput 
multimodality imaging pipeline to phenotype the mouse knee. We analyze 50 randomly 
selected mouse lines, identifying seven (14%) with markedly abnormal phenotypes. A 
systematic prioritization strategy identifies seven further lines, resulting in 14 genes (28%) with 
evidence for a functional role in osteoarthritis pathogenesis. The four leading candidates are 
Pitx1, Bhlhe40, Sh3bp4 and Unk. We interrogate the database of joint phenotypes from 
randomly selected mouse lines with 409 genes differentially expressed in human osteoarthritis 
cartilage. This results in an enriched yield of abnormal joint phenotypes in six (75%) of eight 
lines for which data are available, including Unk. We then apply the pipeline to characterize 
the early features of age-related joint degeneration in one-year old mice and demonstrate its 
sensitivity to detect disease onset as well as surgically provoked late-stage disease, paving 
the way for application to analysis of drug intervention studies. Finally, we phenotype 
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previously generated CRISPR/Cas9 mutant mice with a Thr92Ala polymorphism in the Dio2 
gene that is orthologous to the human variant associated with osteoarthritis susceptibility. The 
Ala92 allele confers protection against early-onset osteoarthritis, challenging current 
understanding with implications for public health.  
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Results 
Invention and optimization of imaging methods 
We established a rapid-throughput joint phenotyping pipeline (OBCD joint pipeline), which 
applies three complementary imaging approaches to characterize features of osteoarthritis in 
mutant mice that include articular cartilage damage and loss, together with abnormalities of 
subchondral bone structure and mineralization (Figure 1). Iodine contrast-enhanced micro-
computerized tomography (ICECT) was developed to determine articular cartilage volume 
(Cg.V), median thickness (Median Cg.Th), maximum thickness (Max Cg.Th), subchondral 
bone volume/tissue volume (SC BV/TV), trabecular thickness (SC Tb.Th), trabecular number 
(SC Tb.N) and tissue mineral density (SC TMD). Joint surface replication (JSR) was invented 
and optimized to quantify articular cartilage surface damage. Subchondral bone X-ray 
microradiography (scXRM) was developed from previous protocols21, 22 to determine 
subchondral bone mineral content (SC BMC) (Figures 1, 2 and Supplementary Figure 1). 
 
Validation of imaging methods 
The OBCD joint pipeline methods were validated by comparison with Osteoarthritis Research 
Society International (OARSI) histological scoring23 of knees from 22-week-old wild-type (WT) 
mice, 12 weeks after destabilization of the medial meniscus (DMM)13, 24. One cohort of WT 
mice (n=16) was phenotyped using ICECT, JSR and scXRM in the OBCD joint pipeline, and 
a second cohort (n=11) was analyzed by OARSI scoring (Figure 1). DMM surgery resulted in 
decreased Cg.V and Max Cg.Th with a marked increase in Cg. damage (Figure 3). This 
cartilage destruction was accompanied by increased SC BV/TV, increased SC Tb.Th, 
decreased SC Tb.N and increased SC BMC (Figure 3 and Supplementary Figure 2). These 
abnormalities were consistent with extensive cartilage damage, synovitis and osteophyte 
formation demonstrated by OARSI-scored histology together with ICECT and JSR (Figure 3 
and Supplementary Figure 2, Supplementary Figure 3 and Supplementary Data 1, 
Supplementary Data 2).  
 7
 
OARSI analysis was also undertaken on three joints that were phenotyped in the OBCD joint 
pipeline and found to have features indicating mild, intermediate and severe osteoarthritis 
following DMM surgery. OARSI scoring was concordant with the severity of abnormalities 
identified by ICECT, JSR and scXRM, thus validating the use of these imaging modalities to 
characterize osteoarthritis (Supplementary Figure 4). 
 
Definition of WT reference ranges 
Phenotype datasets for all parameters were obtained from 100 16-week-old male WT mice. 
Reference ranges, coefficients of variation, estimates of skewness and kurtosis, normality, 
repeatability and power calculations were determined (Supplementary Data 3). The reference 
range for each parameter was defined as either (i) the mean +/- 2.0 standard deviations for 
normally-distributed data, or (ii) the median and 2.5th -97.5th percentile range for non-normally 
distributed data (Supplementary Figure 1). 
 
Identification of osteoarthritis genes 
To identify genes that cause osteoarthritis, we used the OBCD joint pipeline to analyze knees 
from 16-week-old male mice (n=3-7) from 50 randomly selected mutant lines generated in an 
identical C57BL6/N;C57BL6/NTac genetic background (Supplementary Data 4). 
 
Rigorous statistical approaches were used to determine which lines displayed robust outlier 
phenotypes (Figure 1, Supplementary Data 4 and 5). Lines with outlier phenotypes were 
identified: (i) when the mean value for an individual parameter was outside the WT reference 
range; (ii) by using the Wilcoxon rank sum statistical test to analyze all individual phenotype 
measurements rather than only mean values, with a Bonferroni multiple-testing correction for 
the effective number of tests (Supplementary Data 5); and (iii) by calculation of Mahalanobis 
distances to ensure that lines with significantly abnormal phenotypes were not overlooked 
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when they resulted from simultaneous but smaller variances in multiple phenotype 
parameters. 17 lines (34%) had at least one abnormal phenotype parameter outside the 
reference range, 12 (24%) of which had increased cartilage surface damage. 18 lines (36%) 
were outliers after statistical analysis using the Wilcoxon test with Bonferroni correction, and 
10 (20%) were outliers following Mahalanobis analysis. Overall, 25 individual lines (50%) had 
an abnormal joint phenotype based on these criteria (Figure 1). Increased body weight was 
not present in any mutant line (Supplementary Data 4). Furthermore, body weight did not 
correlate with any joint phenotype parameter in wild-type mice (P<0.05, Spearman correlation, 
Supplementary Data 6). 
 
The effect of gene deletion on phenotype severity was assessed by scoring whether joint 
abnormalities were (i) reference range outliers, (ii) outliers based on the Bonferroni-corrected 
Wilcoxon test, (iii) outliers after Mahalanobis analysis, and by considering whether joint 
pathology included abnormalities of cartilage morphology, cartilage integrity and/or 
subchondral bone structure (Supplementary Data 7). Of the 25 lines with an outlier phenotype, 
the top seven ranked lines with the most severe abnormalities were a cluster of 6 microRNAs 
(ClusterXN1: miR-106a, miR-18b, miR-19b-2, miR-20b, miR-92-2, miR-363), paired like 
homeodomain 1 (Pitx1), fibroblast growth factor binding protein 1 (Fgfbp1), Josephin domain 
containing 1 (Josd1), SH3 domain binding protein 4 (Sh3bp4), unkempt family zinc finger 
(Unk), and zinc finger protein 341 (Zfp341) (Figure 1, Supplementary Data 7). 
 
Prioritization of 25 mouse lines with outlier phenotypes 
An informatics strategy was used to investigate biological plausibility and prioritize the 25 
candidate genes based on (i) additional skeletal consequences of gene deletion, (ii) gene 
expression in skeletal cells and tissues, (iii) association with human disease, and (iv) 
structured literature searching. Each criterion was assigned a score and scores were summed 
to rank genes in order of priority. 
 
 9
Additional skeletal consequences of gene deletion were investigated by: (i) identifying whether 
mutant mice had abnormalities of bone structure and strength16, (ii) IMPC IMPReSS 
phenotype screening, (iii) analysis of the skeleton in embryos from lines in which homozygous 
gene deletion was lethal or resulted in sub-viability25, and (iv) determining whether mutations 
of the same gene had skeletal abnormalities identified in Mouse Genome Informatics (MGI) 
databases or the published literature. The top ranked genes with major effects on skeletal 
phenotype were Pitx1, basic helix-loop-helix family member e40 (Bhlhe40), SR-related CTD 
associated factor 11 (Scaf11) and SMG9 nonsense mediated mRNA decay factor (Smg9) 
(Figure 1, Supplementary Data 7). 
 
Gene expression in skeletal cells and tissues was investigated by interrogation of (i) MGI and 
BioGPS26 databases, and (ii) transcriptome datasets from human chondrocytes and 
cartilage27, 28, mouse and human osteoblasts26, 28, mouse osteocytes19, and mouse and human 
osteoclasts26, 28. The top ranked genes with expression enriched in cartilage and bone 
compared to non-skeletal tissues were Bhlhe40, Pitx1, collagen type IV alpha 2 chain (Col4a2) 
and Sh3bp4 (Figure 1, Supplementary Data 7). 
 
Association with human disease was investigated by searching MGI and Online Mendelian 
Inheritance in Man (OMIM) databases to determine whether mutations in any of the 25 genes 
resulted in monogenic diseases affecting the skeleton. To determine whether any gene loci 
were associated with arthritis or other skeletal phenotypes, we interrogated the European 
Bioinformatics Institute GWAS catalogue. The top ranked genes associated with arthritis and 
skeletal disease in humans were Pitx1, coiled-coil domain containing 6 (Ccdc6), HECT and 
RLD domain containing E3 ubiquitin protein ligase family member 1 (Herc1), nebulette (Nebl), 
Sh3bp4 and Zfp341 (Figure 1, Supplementary Data 7). 
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Structured literature searching of PubMed and Google Scholar databases identified Bhlhe40, 
Col4a2 and Pitx1 as the top ranked candidate genes with publications related to arthritis or 
skeletal cell biology (Figure 1, Supplementary Data 7). 
 
Together, consideration of additional skeletal phenotypes, gene expression, association with 
human disease and the published literature prioritized 10 lines (Pitx1, Bhlhe40, Scaf11, Smg9, 
Col4a2, Sh3bp4, Ccdc6, Herc1, Nebl and Zfp341). 11 (44%) of the 25 randomly selected 
candidates with outlier phenotypes (Arhgap30, Arrdc5, ClusterXN1, Cpgi81, Gsdme, Hpf1, 
Josd1, Mkrn2, Scaf11, Slamf9, Smg9) had no prior links to osteoarthritis or skeletal biology 
based on association with human disease and structured literature searching, whereas only 
two (20%) of the 10 prioritized candidates (Scaf11, Smg9) had no prior association (Figure 1, 
Supplementary Data 7). 
 
Combining findings from informatics prioritization with the seven lines with the most severe 
joint phenotypes (ClusterXN1, Pitx1, Fgfbp1, Josd1, Sh3bp4, Unk, Zfp341) identified 14 genes 
with strong evidence from independent sources for a functional role in osteoarthritis 
pathogenesis (Pitx1, Bhlhe40, Scaf11, Smg9, Col4a2, Sh3bp4, Ccdc6, Herc1, Nebl, Zfp341, 
ClusterXN1, Fgfbp1, Josd1, and Unk). The four genes with the strongest overall evidence 
were Pitx1, Bhlhe40, Sh3bp4 and Unk (Figure 1, Supplementary Data 7). 
 
Severe early onset osteoarthritis in Pitx1+/- mice 
Pitx1 is a homeobox transcription factor required for patterning, and specification of hindlimb 
morphology29, 30. Homozygous Pitx1-/- mutations cause post-natal lethality with gross 
morphological abnormalities affecting the hindlimb skeleton29, 30. Genomic rearrangements at 
the human PITX1 locus result in homeotic arm-to-leg transformations in Liebenberg syndrome 
(OMIM 186550), and misexpression of Pitx1 in the mouse forelimb recapitulates this 
phenotype31. Haploinsufficiency for Pitx1 in mice and humans results in clubfoot and other leg 
malformations, demonstrating hindlimb development is sensitive to Pitx1 gene dosage32. 
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Heterozygous Pitx1+/- mice had the most severe phenotype observed in this study, with 
extensive joint damage affecting both compartments of the knee including decreased articular 
cartilage volume and thickness, and increased areas of complete loss or severe erosion of 
articular cartilage. The Pitx1+/- phenotype was as severe as the extensive joint damage 
observed in 22-week-old WT mice 12 weeks after DMM surgery (Figure 3 and Supplementary 
Figure 2a and c). Osteophytes were detected in 5/7 Pitx1+/- mice (Supplementary Data 8). 
Accordingly, histology confirmed severe osteoarthritis with extensive vertical clefts in articular 
cartilage and areas of erosion over 50-75% of the articular surface to the calcified cartilage 
beneath (Figure 3, Supplementary Figure 2c and Supplementary Data 4).  
 
Early onset osteoarthritis in Bhlhe40-/- and Sh3pb4-/- mice 
Bhlhe40-/- mice had decreased median and maximum Cg.Th affecting both compartments of 
the knee. Further evidence of spontaneous damage included vertical clefts in the articular 
cartilage surface extending down to the layer of chondrocytes immediately below the 
superficial layer, together with some loss of surface lamina (Figure 4, Supplementary Figure 
5 and Supplementary Data 4). No osteophytes were detected in Bhlhe40-/- mice 
(Supplementary Data 8). Bhlhe40 is a widely expressed transcription factor involved in 
regulation of cell proliferation, differentiation, apoptosis and senescence33. Bhlhe40 
expression is enriched in skeletal tissues (Supplementary Data 7), specifically in proliferating 
and differentiating chondrocytes during endochondral ossification34, and is elevated in 
response to hypoxia35, bone morphogenetic protein-2 (BMP2) and transforming growth factor-
 (TGF) but suppressed by parathyroid hormone36. Bhlhe40 stimulates terminal chondrocyte 
and osteoblast differentiation36, 37, and has been implicated in bone loss in chronic 
periodontitis38. Deletion of Bhlhe40 in mice results in increased bone mineral content and 
density (Supplementary Data 7), but a role in osteoarthritis pathogenesis has not been 
postulated and BHLHE40 has not been associated with osteoarthritis in GWAS. 
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Overall, young adult Bhlhe40-/- mice display thinning of articular cartilage, suggesting a role in 
disease onset that involves the key hypoxia, BMP2, TGF and PTH signalling pathways39, 40, 
41, 42. 
 
Sh3bp4-/- mice had decreased Cg.V and median and maximum Cg.Th, together with increased 
articular cartilage surface damage affecting the lateral compartment. Histology revealed 
moderate osteoarthritis with articular cartilage fibrillations and vertical clefts over <25% of the 
articular surface extending to the calcified cartilage beneath (Figure 4, Supplementary Figure 
5 and Supplementary Data 4). No osteophytes were detected in Sh3bp4-/- mice 
(Supplementary Data 8). Sh3bp4 is a poorly characterized SH3 domain binding protein 
involved in transferrin receptor (TfR) internalization43, fibroblast growth factor receptor (FGFR) 
trafficking44, mammalian target of rapamycin (mTOR) signalling45 and inhibition of the Wnt 
pathway46.  SH3BP4 has not been associated with osteoarthritis in GWAS. 
 
In summary, Sh3bp4-/- mice display loss of articular cartilage and moderate cartilage damage.   
Sh3bp4 thus represents an osteoarthritis susceptibility gene, the deletion of which accelerates 
joint damage. Its role in disease pathogenesis may involve the key TfR, FGFR, mTOR and 
Wnt signalling pathways, which regulate bone and cartilage homeostasis and tissue repair47, 
48, 49, 50. 
 
Additional applications of the OBCD joint pipeline 
The development of joint phenotyping methods to investigate mutant mice demonstrates the 
power of unbiased functional genomics in osteoarthritis gene discovery. Open access 
availability of IMPC mouse lines provides a rich resource for investigation of disease 
mechanisms and the identification and testing of preventive or disease modifying drugs. Here 
we describe three further distinct applications of the phenotyping pipeline that demonstrate 
how the OBCD joint phenotype database can be leveraged to add value to studies of human 
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osteoarthritis and how the imaging techniques can be applied to address additional 
hypotheses. 
 
Knockout mice for genes differentially expressed in human OA cartilage  
Phenotyping genetically modified mouse models is a powerful method to functionally annotate 
potential disease susceptibility genes identified in human studies. We interrogated the OBCD 
database of joint phenotypes from randomly selected mouse lines to annotate the function of 
409 genes differentially expressed in low- versus high-grade articular cartilage in osteoarthritis 
patients51. Phenotype data in 16-week-old mice were available from eight differentially 
expressed genes (Unk, Josd1, gasdermin E (Gsdme), Rho GTPase activating protein 30 
(Arhgap30), Ccdc6, Col4a2, methyl-CpG binding domain protein 1 (Mbd1) and staufen 
double-stranded RNA binding protein 2 (Stau2)). Mutation of six (75%) differentially expressed 
genes in mice resulted in joint abnormalities whereas deletion of the other two (25%) (Mbd1, 
Stau2) had no effect (Supplementary Data 4 and 5). This compares with 14 out of 50 randomly 
selected lines (28%) with strong evidence for a functional role in osteoarthritis following 
prioritization in this study (P=0.01582, Fisher’s exact test). This enrichment of signal supports 
interrogation of the OBCD phenotype database to accelerate functional gene discovery in 
osteoarthritis. Combining complementary mouse and human gene discovery approaches 
demonstrates synergy, especially as none of the genes identified have been associated with 
osteoarthritis in GWAS. 
 
Unk-/- mice had decreased articular cartilage volume in the LTP and decreased maximum 
cartilage thickness with increased surface damage affecting the MTP (Figure 5, 
Supplementary Figure 6, Supplementary Data 4, 5 and 7). No osteophytes were detected in 
Unk-/- mice (Supplementary Data 8). Mean body weight was 2.49 SDs below the wild-type 
mean (Supplementary Data 4). UNK is an RNA binding zinc finger protein expressed in 
developing brain that controls neuronal morphology52. UNK is also expressed in the skeleton 
(Supplementary Data 7). Unk-/- mice display articular cartilage loss with early cartilage damage 
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indicating Unk is a protective osteoarthritis susceptibility gene. Downregulation of UNK at the 
RNA and protein levels in high-grade osteoarthritis cartilage in humans suggests a role in 
disease pathogenesis. 
 
Josd1-/- mice had decreased median and maximum cartilage thickness affecting both joint 
compartments and increased articular cartilage surface damage affecting the lateral 
compartment (Figure 5, Supplementary Figure 6, Supplementary Data 4, 5 and 7). No 
osteophytes were detected in Josd1-/- mice (Supplementary Data 8). JOSD1 is a widely 
expressed deubiquitinating enzyme that may play a role in regulation of cell membrane 
dynamics53. It stabilizes SOCS1, an important negative regulator of cytokine signalling54, 55, 
and JOSD1 mRNA is upregulated in high-grade osteoarthritis cartilage (Figure 5), suggesting 
a protective role for JOSD1 in osteoarthritis. 
 
Gsdme-/- mice had increased articular cartilage surface damage affecting the lateral 
compartment (Figure 5, Supplementary Figure 6, Supplementary Data 4, 5 and 7). No 
osteophytes were detected in Gsdme-/- mice (Supplementary Data 8). Gasdermin E is a 
member of a family of proteins that facilitate necrotic programmed cell death (pyroptosis) 
following cleavage by caspase-356. Pyroptosis has recently been shown to promote knee 
osteoarthritis57, 58, and upregulation of Gsdme in high-grade osteoarthritis cartilage (Figure 5), 
supports a role for gasdermin E in disease progression. 
 
Arhgap30-/- mice had increased articular cartilage surface damage affecting the lateral 
compartment and a significant outlier phenotype following Mahalanobis analysis 
(Supplementary Data 4and 7). Arhgap30 encodes a Rho GTPase implicated in cell 
proliferation, migration and invasion acting via inhibition of Wnt59. Its putative role and 
increased expression in high-grade osteoarthritis cartilage (Figure 5), suggests involvement 
of ARHGAP30 in cartilage repair mechanisms during osteoarthritis pathogenesis. 
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Ccdc6-/- mice had increased articular cartilage surface damage affecting the medial 
compartment (Supplementary Data 4and 7). Ccdc6 is a cell cycle checkpoint regulator that 
facilitates cell survival60. CCDC6 was associated with heel BMD in a large GWAS19 and Ccdc6-
/- mice have decreased bone strength (Supplementary Data 7). Concordant with upregulation 
of CCDC6 in high-grade osteoarthritic cartilage (Figure 5), CCDC6 was differentially 
expressed in a meta-analysis of gene expression profiling in synovial tissue from osteoarthritis 
cases and controls61. Overall, CCDC6 represents an osteoarthritis susceptibility gene, deletion 
of which may contribute to development of osteoarthritis by actions in both cartilage and the 
synovium.  
 
Col4a2-/- mice had increased articular cartilage surface damage affecting the lateral 
compartment (Supplementary Data 4). The collagen type IV alpha 2 chain is a major 
component of vascular basement membrane62, but is also present in skeletal basement 
membranes due to expression in bone cells (Supplementary Data 7). COL4A2 was 
differentially expressed in osteoarthritis synovium61, in knee joints following DMM surgery63, 
in a time course analysis following DMM surgery64, and in articular cartilage biopsies from 
osteoarthritis patients65. The COL4A2 locus was differentially methylated in a genome-wide 
analysis of hip compared to knee osteoarthritis cartilage66. In summary, several lines of 
evidence suggest a role for Col4a2 in the pathogenesis of osteoarthritis and the articular 
cartilage damage in Col4a2-/- mice is consistent with this hypothesis (Figure 1 and 
Supplementary Data 4). 
 
Age-related joint degeneration 
We next studied 4- and 12-month-old WT mice to investigate the effect of ageing. Joints from 
12-month-old mice had features of osteoarthritis compared to 4-month-old juvenile mice. Even 
though articular volume and thickness did not change with age, the 12-month-old mice had 
significantly increased areas of cartilage damage in both lateral and medial compartments. 
Histology revealed an increased maximum OARSI score on the LTP in 12-month-old 
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compared with 4-month-old mice. These changes were accompanied by loss of subchondral 
bone (decreased SC BV/TV, SC Tb.Th and SC Tb.N) in the lateral compartment and increased 
SC BMC in the medial compartment (Figure 6 and Supplementary Figure 7). 
 
Dio2Ala92 mice are protected from osteoarthritis  
We next used the phenotyping pipeline to investigate a mouse model of a common human 
single nucleotide polymorphism previously associated with human osteoarthritis. As proof-of-
concept for functional investigation of signals arising from human genetic association studies, 
we studied the effect of rs225014, a polymorphism in the human DIO2 gene. rs225014 results 
in a substitution at amino acid 92 (Thr92Ala) in the DIO2 enzyme that activates thyroid 
hormones in target cells. The minor allele (Ala92) frequency is estimated at 40%67. rs225014 
was positively associated with osteoarthritis in a genome-wide linkage study that included 
replication in a separate cohort68, but this association was not reproduced in the Rotterdam 
study69 or a later meta-analysis70. Nevertheless, a polymorphism in the DIO2 promoter 
(rs12885300) has been associated with hip geometry in genome-wide linkage studies. While 
minor alleles at rs225014 and rs12885300 were associated with opposite osteoarthritis 
outcomes, a haplotype combining both was associated with increased disease susceptibility71. 
Overall, these findings implicate regulation of local thyroid hormone availability in the 
pathogenesis of osteoarthritis and are consistent with well-known actions of thyroid hormones, 
which stimulate hypertrophic chondrocyte differentiation72 and expression of cartilage matrix 
degrading enzymes73. Nevertheless, DIO2 has not been associated with osteoarthritis in 
GWAS, and the role of the DIO2 rs225014 polymorphism remains controversial, attracting 
much debate even beyond the osteoarthritis field74, 75, 76. 
 
In vivo studies have demonstrated increased subchondral bone but intact articular cartilage in 
Dio2-/- knockout mice77. Dio2-/- mice have decreased calreticulin expression in articular 
cartilage78, a gene implicated in cartilage thinning in response to mechanical loading79, and 
are protected from cartilage damage following forced exercise. By contrast, increased DIO2 
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expression resulted in negative effects on chondrocyte function and homeostasis in vitro80 and 
DIO2 expression was increased in articular cartilage from osteoarthritis patients81. 
Furthermore, cartilage-specific overexpression of Dio2 in transgenic rats resulted in cartilage 
destruction82. Together, these studies suggest that decreased DIO2 expression and reduced 
thyroid hormone availability in the joint may protect against osteoarthritis, whereas increased 
DIO2 expression may increase susceptibility. 
 
To test this hypothesis, we analyzed the joint phenotypes of Dio2Thr92 and Dio2Ala92 mutant 
mice previously generated using the CRISPR/Cas9 system74. The Thr92Ala polymorphism 
results in decreased enzyme activity and impaired conversion of the prohormone thyroxine 
(T4) to the active hormone triiodothyronine (T3) reducing local thyroid hormone signalling74. 
Analysis of joints from 16-week-old male mice demonstrated features of early onset 
osteoarthritis in Dio2Thr92 mice compared to Dio2Ala92 mice.  Dio2Thr92 mice had decreased 
cartilage volume and median thickness with increased articular cartilage damage (Figure 7 
and Supplementary Figure 8). By contrast, Dio2Ala92 mutants had no signs of osteoarthritis, 
indicating a protective role for the Ala92 polymorphism and providing the first functional 
evidence of a role for this candidate DIO2 polymorphism in vivo. The data provide further 
evidence that decreased thyroid hormone signalling is protective against osteoarthritis.
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Discussion 
The molecular mechanisms that initiate and drive osteoarthritis progression and their genetic 
origins are largely unknown. We developed rapid-throughput joint phenotyping methods to 
identify abnormal joint phenotypes in mutant mice, identifying 14 genes with strong functional 
evidence for involvement in osteoarthritis pathogenesis. Previous approaches to mouse joint 
phenotyping have used modifications to standard µCT methods, including the use of cartilage 
staining or phase-contrast, while others have used confocal microscopy83, 84, 85, 86, 87, 88, 89, 90, 91, 
92, 93, 94. Here, we combine three complementary methods; iodine contrast-enhanced micro-
computerized tomography (ICECT), joint surface replication (JSR) and subchondral bone X-
ray microradiography (scXRM), in the first comprehensive multiplex mouse joint phenotyping 
pipeline. One important consideration regarding the highly sensitive JSR method is the very 
low level of cartilage damage that is present in wild type mice (0-2.8%). Thus, the method may 
be less reliable for quantitation of decreased cartilage damage in phenotype screening 
studies. Nevertheless, the method correlates well with OARSI histology and provides reliable 
and sensitive detection of increased cartilage damage, which is a pathognomonic feature of 
osteoarthritis.  Furthermore, it is particularly useful in studies of mice with protective mutations 
that have been challenged by DMM provocation surgery providing such studies are 
adequately powered.   
 
To demonstrate the broad utility of this joint phenotyping pipeline we describe four distinct 
applications (i) Screening of randomly selected KO lines (ii) Analysis of knockout mice with 
deletion of genes differentially expressed in human OA cartilage, (iii) Analysis of mice with 
age-related joint degeneration and (iv) Analysis of a mouse model of a common human single 
nucleotide polymorphism associated with osteoarthritis. 
 
We first performed joint phenotyping in 50 randomly selected IMPC knockout lines generated 
by the Sanger Institute and identified one or more outlier parameters in 50% of lines. This is 
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similar to the frequency of outlier parameters identified during bone phenotyping of randomly-
selected IMPC knockout mice16, 17, 19 and consistent with the numerous independent loci 
associated with osteoarthritis1, 2, 3 and osteoporosis17, 19 in large scale GWAS. We, therefore, 
developed a robust and unbiased prioritisation pipeline that identified only those genes with 
multi-parameter joint abnormalities (n=14), which were further prioritised based on biological 
evidence, plausibility and relevance to human disease, finally highlighting 4 out of 50 genes 
(Bhlhe40, Pitx1, Sh3bp4 and Unk).   
 
Pitx1+/- mice had the most severe and extensive joint destruction in these studies, with severe 
erosions, complete loss of articular cartilage and osteophyte formation. Decreased PITX1 
mRNA expression in primary human articular chondrocytes, reduced PITX1 protein in 
histological sections of human osteoarthritic cartilage, and increased subchondral bone 
thickening in preliminary studies of ageing Pitx1+/- mice are all consistent with an important 
role for PITX1 in osteoarthritis pathogenesis95. Overall, we show that heterozygous deletion 
of Pitx1, a critical developmental gene, results in severe early onset joint damage. Pitx1 is 
thus an osteoarthritis gene with a key role in disease onset and progression that likely involves 
its effects on joint morphology and the developmental programmes that are re-initiated during 
disease progression.  
 
We exploited our joint phenotype database to characterize to functions of six candidate genes 
differentially expressed in human osteoarthritis cartilage. These studies identify roles for Unk, 
Josd1, Gsdme, Arhgap30, Ccdc6 and Col4a2 in the pathogenesis of osteoarthritis. Unk-/- mice 
were also prioritized as one of four lines with the strongest combined evidence for a key 
functional role in osteoarthritis pathogenesis, while Josd1-/- mice were one of seven lines with 
the most severely abnormal joint phenotype (Figure 1 and Supplementary Data 7). Overall, 
these findings demonstrate the value of leveraging the combined power of mouse and human 
experimental pipelines to enhance understanding of complex disease. 
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Previous histological studies have only demonstrated the onset of osteoarthritis at 15 months 
of age in wild-type C57BL6 mice96. The current studies, however, clearly define early features 
of age-related joint degeneration in one-year old animals. Thus, our phenotyping methods are 
more economical and have improved sensitivity to detect early osteoarthritis compared to 
current labour- and resource-intensive histological techniques. OBCD joint phenotyping is one 
third of the cost and takes one sixth of the time compared to the current gold standard OARSI 
histological analysis (Supplementary Figure 9, Supplementary Data 9, 10 and 11). In addition 
to identifying genes that provoke early onset of osteoarthritis when deleted, these methods 
now provide efficient opportunities to analyze genes that protect joints from age-related 
degeneration when inhibited or deleted, or for analysis of drug intervention studies. 
 
Finally, we identified a protective role for a minor allele of the DIO2 gene (Ala92). The Ala92 
variant impairs conversion of the prohormone T4 to the active hormone T3 and is 
controversially associated with osteoarthritis. Furthermore, it has been suggested that 
expression of this minor allele underlies the continuing psychological and metabolic symptoms 
experienced by some hypothyroid patients despite restoration of normal serum T4 levels 
following levothyroxine replacement76, 97. As a result, genetic testing and treatment of 
hypothyroid patients with the Ala92 variant using increased doses of levothyroxine (T4) or a 
combination of levothyroxine and liothyronine (T3) has been proposed. Importantly, this 
therapeutic approach, which aims to overcome impaired conversion of T4 to T3 by the Ala92 
variant, may actually have detrimental long-term consequences as our data indicate that 
expression of the Ala92 variant may maintain cartilage integrity. Thus, the allelic imbalance 
that has been reported to increase expression of the Ala92 variant in human osteoarthritis 
cartilage81, may in fact represent a counter-regulatory response in damaged articular cartilage 
to protect against osteoarthritis progression. Our findings underscore the importance of 
caution and further research in this controversial area, and have important public health 
implications, as levothyroxine is the most commonly prescribed drug in the USA and third most 
commonly prescribed in the UK98. 
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In these studies, we performed DMM provocation surgery in 10-week-old mice as described 
originally by Glasson13, 99.  Nevertheless, others now recommend undertaking DMM surgery 
after 12-weeks-of-age because of more advanced skeletal maturity100.  We performed sham 
surgery in the contralateral knee in order to include paired control samples and minimise 
animal numbers in accordance with the principles of reduction, refinement and replacement 
(3Rs). Nevertheless, we acknowledge that sham surgery may influence joint mobility and 
affect phenotype severity100.  This study identifies abnormal joint phenotypes in several 
knockout mice suggesting the deleted genes have important roles in joint development, 
maintenance and repair.  However, such findings do not necessarily indicate that these genes 
represent tractable drug targets in the prevention and treatment of OA.  Nevertheless, we also 
report that CRISPR/Cas9 targeting of a single amino acid in the Dio2 gene identifies a role for 
thyroid hormone signalling in joint homeostasis and has important clinical implications. 
 
In summary, we have shown our joint phenotyping methods have broad applications in 
osteoarthritis research that will accelerate functional gene discovery, advance understanding 
of disease pathogenesis and identify drug targets for this debilitating chronic disease. 
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Rapid-throughput joint phenotyping identifies  osteoarthritis genes 
Knee joints from randomly selected 16-week-old mutant mice generated at the Wellcome 
Trust Sanger Institute (WTSI) for the International Mouse Phenotyping Consortium (IMPC) are 
analyzed by three imaging modalities; iodine contrast-enhanced micro-computerized 
tomography (ICECT), joint surface replication (JSR) and subchondral bone X-ray 
microradiography (scXRM). The methods were validated by comparison with scoring of 
histological sections (Osteoarthritis Research Society International (OARSI) histology after 
destabilization of the medial meniscus (DMM) provocation surgery. 25 mouse lines (3-way 
Venn diagram) had outlier phenotypes relative to wild-type reference data following statistical 
analyses. Further prioritization was based on additional skeletal abnormalities identified in 
mutant mice, gene expression, association with human disease and literature searching. 
Boxes and 4-way Venn diagram show top ranked genes in each category. Pitx1, Bhlhe40, 
Sh3bp4 and Unk were the top ranked genes. Green text: most severely abnormal joint 
phenotypes. Red boxes indicate mutant lines with increased articular cartilage surface 
damage. Source data are provided as a Source Data file. 
 
Figure 2  
Imaging methods 
a. Coronal views of conventional µCT scan of a 16-week-old wild-type tibia (top left) and 
ICEµCT scan (top right), at 2m voxel size; mineralized tissue is white. In ICEµCT scan 
contrast agent at similar X-ray absorption to mineralized tissue; soft tissue including articular 
cartilage is black. Coronal and sagittal views of ICEµCT scans with VOIs (volumes of interest) 
scaled according to a-b (medial-lateral) and c-d (anterior-posterior) tibial dimensions, and 
positioned midway between plateau edges (medial plateau, MTP, e-f, lateral plateau, LTP, g-
h, with a 7% shift medially). Plateau midpoints: dashed lines. M: medial, L: lateral, A: anterior, 
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P: posterior. ICEµCT VOIs used for quantitative analyses (MTP, bottom left, LTP, bottom 
right); subchondral bone (blue); articular cartilage (red). Scale bars = 500m. 
b. Upper images: surface of disarticulated 16-week-old wild-type mouse tibia; limbs immersed 
in impression medium for moulding; mould (brown) overlaid with casting resin; surface of 
mould after removal of cast; surface of cast. Lower images: detail of mould surface; detail of 
cast surface; carbon-coated cast; back-scattered electron-scanning electron microscopy 
(BSE-SEM) image of whole tibia; high-power showing fibrillations in articular cartilage surface 
following DMM surgery. 
c. Upper images: BSE-SEM view of lateral tibial plateau; selection of whole plateau region for 
analysis; automated identification of surface damage edges; thresholding of damage to 
capture all damage areas; damage detection. Lower images: high power views demonstrate 
damage detail. Scale bars = 500m (upper), 100m (lower). 
d. Upper images: Faxitron MX20; 16-week-old wild-type mouse tibia alongside aluminium 
(left), plastic (right) and steel (bottom) standards; plain X-ray grey scale image of tibia and 
standards; greyscale images are pseudocoloured according to a 16 colour look-up table in 
which low bone mineral content (BMC) is yellow and high BMC is pink. Lower images: 
pseudocoloured image of proximal tibia with scaled (to width of tibia, white line) subchondral 
regions of interest (ROI), white boxes (LTP; lateral tibial plateau, MTP; medial tibial plateau); 
high power pseudocoloured views of LTP and MTP ROIs; grey scale pixel distribution in 
relation to standards; grey scale distribution stretched to plastic and steel standards. Scale 
bar = 1mm. mm; millimeter, mgHA/cm3; milligrams of hydroxyapatite/cubic centimeter. 
 
Figure 3 
Severe early onset osteoarthritis in Pitx1+/- mice is similar to extent of joint damage 
following osteoarthritis provocation surgery 
a. Iodine contrast enhanced CT images of medial tibial plateau articular cartilage (red) and 
subchondral bone (blue) from 22-week-old wild type (WT) male mice 12 weeks after sham 
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operation or following destabilization of medial meniscus surgery (DMM; n=11) to provoke 
osteoarthritis, and 16-week-old male WT and heterozygous Pitx1+/- mice (n=7). Graphs show 
decreased articular cartilage volume (Cg.V) and maximum articular cartilage thickness (Max 
Cg.Th). 
b. Back-scattered electron-scanning electron microscopy images of tibial plateau joint surface 
replicas from sham and DMM-operated WT mice, and WT and Pitx1+/- mice. Graphs show 
increased articular cartilage (Cg.) damage area. 
c. X-ray microradiography images of proximal tibia and the medial tibial plateau subchondral 
bone region of interest (dashed box) from sham and DMM-operated WT mice, and WT and 
Pitx1+/- mice in which greyscale images are pseudocoloured according to a 16 colour look-up 
table in which low bone mineral content (BMC) is yellow and high BMC is pink. Graphs show 
increased subchondral BMC (SC BMC; DMM only). 
d. Coronal sections of knee joint compartments stained with Safranin-O/Fast green from sham 
and DMM-operated WT mice, and from WT and two examples of Pitx1+/- mice with extensive 
joint destruction. Graph shows the maximum OARSI score on the medial tibial plateau in 
DMM-operated mice (n=11). Arrows indicate areas of cartilage destruction. Orange circles: 
individual mutant samples, black horizontal lines: sample mean. Grey boxes: reference ranges 
derived from 100 wild-type samples. For normally distributed parameters (SC BMC), reference 
range is 2 standard deviations above and below the mean (dashed line). For non-normally 
distributed parameters (Cg.V, Max Cg.Th, Cg. Damage Area), reference range is the 2.5th-
97.5th percentile, and dashed line is the median.  Scale bars = 100m (a, b, d) and 1mm (c). 
DMM vs. Sham: *P<0.05, **P<0.01, ***P<0.001, 2-tailed Wilcoxon matched pairs signed rank 
test for Cg.V (P=0.00131), Max. Cg.Th (P=0.017334), Cg. Damage Area (P=0.000031) and 
Max. OARSI score (P=0.000977), and paired 2-tailed t-test for SC BMC (P=0.000477). Pitx1+/-
: *P<0.00568, ***P<0.0001, Bonferroni-corrected 2-tailed Wilcoxon rank sum test. Cg.V: 
P=0.00008, Max. Cg.Th: P=0.00319, Cg. Damage area: P=0.00001. mm; millimeter. Source 




Early onset osteoarthritis in Bhlhe40-/- and Sh3pb4-/- mice 
a. Iodine contrast enhanced CT images of lateral tibial plateau articular cartilage (red) and 
subchondral bone (blue) from 16-week-old wild type (WT) and homozygous Bhlhe40-/- and 
Sh3bp4-/- mice. Graphs show articular cartilage volume (Cg.V) and median articular cartilage 
thickness (Median Cg.Th) in Bhlhe40-/- (n=3) and Sh3bp4-/- (n=5) mice.  
b. Back-scattered electron-scanning electron microscopy images of lateral tibial plateau joint 
surface replicas from WT, Bhlhe40-/- and Sh3bp4-/- mice. Graph shows articular cartilage (Cg) 
damage. 
c. X-ray microradiography images of proximal tibia and the lateral tibial plateau subchondral 
bone region of interest (dashed box) from WT, Bhlhe40-/- and Sh3bp4-/- mice in which 
greyscale images are pseudocoloured according to a 16 colour look-up table in which low 
bone mineral content (BMC) is yellow and high BMC is pink. Graph shows no change in 
subchondral BMC (SC BMC). 
d. Coronal sections of lateral knee joint compartment stained with Safranin-O/Fast green from 
WT, Bhlhe40-/- and Sh3bp4-/- mice (n=3 sections from 1 mouse each). Arrows indicate areas 
of cartilage damage. Orange circles: individual mutant samples, black horizontal lines: sample 
mean. Grey boxes: reference ranges derived from 100 wild-type samples. For normally 
distributed parameters (Cg.V, SC BMC), reference range is 2 standard deviations above and 
below the mean (dashed line). For non-normally distributed parameters (Median Cg.Th, Cg. 
Damage Area), reference range is the 2.5th-97.5th percentile, and dashed line is the median.  
Scale bars = 100m (a, b, d) and 1mm (c). *P<0.00568, **P<0.001, Bonferroni-corrected 2-
tailed Wilcoxon rank sum test. Cg.V: P=0.00311 (Sh3bp4-/-), Median Cg.Th: P=0.00469 
(Bhlhe40-/-), P=0.00081 (Sh3bp4-/-), Cg. Damage Area: P=0.00282 (Sh3bp4-/-).  mm; 




Early onset osteoarthritis in mice with deletion of genes differentially expressed in 
human osteoarthritis cartilage 
a. 16-week-old mice with deletion of candidate genes differentially expressed in osteoarthritic 
human articular cartilage (Unk, Josd1, Gsdme, Arhgap30, Ccdc6, Col4a2, Mdb1 and Stau2) 
were investigated for osteoarthritis phenotypes. 
b. Differential expression (log fold change, logFC) of human orthologues of candidate genes 
in low-grade versus high-grade osteoarthritis in human articular cartilage samples. Genes with 
significantly increased expression in high-grade osteoarthritis cartilage shown in green and 
those with decreased expression in red. 
c. Iodine contrast enhanced CT images of lateral tibial plateau articular cartilage (red) and 
subchondral bone (blue) from wild type (WT), Unk-/-, Josd1-/- and Gsdme-/- mice. Graphs show 
articular cartilage volume (Cg.V) and maximum articular cartilage thickness (Max Cg.Th) in 
Unk -/- (n=4), Josd1 -/- (n=6) and Gsdme-/- (n=4) mice. 
d. Back-scattered electron-scanning electron microscopy images of tibial plateau joint surface 
replicas from WT, Unk-/-, Josd1-/- and Gsdme-/- mice. Graph shows articular cartilage (Cg) 
damage. 
e. X-ray microradiography images of proximal tibia and the lateral tibial plateau subchondral 
bone region of interest (dashed box) from WT, Unk-/-, Josd1-/- and Gsdme-/- mice in which 
greyscale images are pseudocoloured according to a 16 colour look-up table in which low 
bone mineral content (BMC) is yellow and high BMC is pink. Graph shows subchondral BMC 
(SC BMC Orange circles: individual mutant samples, black horizontal lines: sample mean. 
Grey boxes: reference ranges derived from 100 wild-type samples. For normally distributed 
parameters (Cg.V, Max. Cg.Th, SC BMC), reference range is 2 standard deviations above 
and below the mean (dashed line). For non-normally distributed parameters (Cg. Damage 
Area), reference range is the 2.5th-97.5th percentile, and dashed line is the median. Scale 
bars = 100m (c, d) and 1mm (e). *P<0.00568, Bonferroni-corrected 2-tailed Wilcoxon rank 
sum test. Cg.V: P=0.00215 (Unk-/-), Max. Cg.Th P=0.00362 (Josd1-/-), Cg. Damage Area: 
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P=0.00563 (Josd1-/-), P=0.00355 (Gsdme-/-). mm; millimeter. Source data are provided as a 
Source Data file. 
 
Figure 6 
Age-related joint degeneration 
a. Cohorts (n=6) of young adult (4 months) and aged (12 months) wild type (WT) mice were 
analyzed by iodine contrast enhanced CT (ICECT), joint surface replication (JSR) and 
subchondral X-ray microradiography (scXRM). 
b. ICECT images of lateral tibial plateau articular cartilage (red) and subchondral bone (blue). 
Graphs show median articular cartilage thickness (Median Cg.Th) and subchondral bone 
BV/TV (SC BV/TV). 
c. Back-scattered electron-scanning electron microscopy images of lateral tibial plateau JSRs. 
Graph shows articular cartilage (Cg) damage. 
d.   ScXRM images of proximal tibia and the lateral tibial plateau subchondral bone region of 
interest (dashed box) in which greyscale images are pseudocoloured according to a 16 colour 
look-up table in which low bone mineral content (BMC) is yellow and high BMC is pink. Graph 
shows subchondral BMC (SC BMC). 
e. Coronal sections of lateral knee joint compartment stained with Safranin-O/Fast green (n=6 
mice/group). Graph shows maximum OARSI histological scores. Arrow indicates cartilage 
damage. Scale bars = 100m (b, c, e) and 1mm (d). *P<0.05, **P<0.01, 2-tailed t-test (SC 
BV/TV, P=0.0082) or 2-tailed Wilcoxon rank sum test (Cg. Damage area, P=0.0022 and Max. 
OARSI score, P=0.0240). mm; millimeter. Source data are provided as a Source Data file. 
 
Figure 7 
Dio2Ala92 mice are protected from osteoarthritis 
a. 16-week-old mice with Dio2 polymorphisms homologous to the Thr92Ala polymorphism in 
human DIO2 (Dio2Thr92, n=9 and Dio2Ala92, n=10) were analyzed by iodine contrast enhanced 
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CT (ICECT), joint surface replication (JSR) and subchondral X-ray microradiography 
(scXRM). 
b. ICECT images of medial tibial plateau articular cartilage (red) and subchondral bone 
(blue). Graphs show articular cartilage volume (Cg.V) and median articular cartilage thickness 
(Median Cg.Th). 
c. Back-scattered electron-scanning electron microscopy images of medial tibial plateau 
JSRs. Graph shows articular cartilage (Cg) damage. 
d. ScXRM images of proximal tibia and the medial tibial plateau subchondral bone region of 
interest (dashed box) in which greyscale images are pseudocoloured according to a 16 colour 
look-up table in which low bone mineral content (BMC) is yellow and high BMC is pink. Graph 
shows subchondral BMC (SC BMC). Scale bars = 100m (b, c) and 1mm (d). *P<0.05, 
**P<0.01, 2-tailed Wilcoxon rank sum test. Cg.V: P=0.019, Median Cg.Th: P=0.006, Cg. 
Damage area: P=0.016. Source data are provided as a Source Data file. 




Mouse lines generated in this study have been deposited in the European Mutant Mouse 
Archive (EMMA; https://www.infrafrontier.eu/) or are available on request. Animal experiments 
were performed and reported in accordance with ARRIVE guidelines101. All animal 
experiments were conducted under licence at Imperial College (project licence PPL70/8785) 
and the Wellcome Trust Sanger Institute (project licence P77453634 and PPL80/2485) in 
accordance with the Animals (Scientific Procedures) Act 1986 and recommendations of the 
Weatherall report. Animal experiments were approved by the Sanger or Imperial College 
Hammersmith Campus Animal Welfare Ethical Review Bodies (AWERB) as appropriate. 
Studies performed at the University of Chicago were approved by the Institutional Animal Care 
and Use Committee (IACUC) at Rush University Medical Center (16-077 and 15-033). Male 
mice were used for all joint phenotype analyses. 
 
IMPC wild-type and mutant mouse strains 
Samples from 16-week old male wild-type (WT) and genetically-modified mice designed with 
deletion alleles on the C57BL/6N Taconic;C57BL/6N background were generated as part of 
the Wellcome Trust Sanger Institute’s (WTSI) Mouse Genetics Project, part of the International 
Mouse Phenotyping Consortium (IMPC; http://www.mousephenotype.org). Details on back-
crossing status, health status, administered drug and procedures, husbandry and specific 
conditions (including housing, food, temperature and cage conditions) have been reported 
previously102, 103 with the exception that temperature was 21±2°C, humidity was 55±10%, the 
diet used was Mouse Breeder Diet 5021 (Labdiet, London, UK) and the IMPReSS screen had 
4 fewer tests (hair phenotyping, open field, hot plate and stress induced hypothermia). Further 
details available on request. Mouse strains, genotypes and Research Resource Identifiers 
(RRIDs) are included in Supplementary Data 12.  Samples from male mice were used for the 
OBCD joint phenotyping pipeline and samples from females were used for the OBCD bone 
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phenotyping pipeline.  The rationale that justified this approach was that (i) the gold-standard 
DMM surgical provocation model for osteoarthritis is 100% penetrant in male mice but has 
variable penetrance in females24, 99, and (ii) the ovariectomy provocation model for post-
menopausal osteoporosis can only be performed in females. 
 
Wild-type male mice for provocation studies 
Mice were housed at Imperial College London in individually ventilated cages (Techniplast, 
UK) on a 12h light/dark cycle at 20-23°C with humidity of 45-65%. Mice were housed in sibling 
groups and given access to chow diet and water ad libitum. Mice were weighed weekly and 
were within a range of 25-35g.  Housing density was between 1-5 animals per cage (up to 
25g) or between 1-4 animals per cage (over 25g). Health status was monitored by screening 
sentinel mice every 3 months, and health reports are available on request. No previous drugs, 
tests or procedures were administered except those specified, and no adverse events 
occurred. Mice were euthanized by exposure to increasing concentrations of CO2 followed by 
cervical dislocation. 
 
For surgical provocation of osteoarthritis, WT C57BL/6 virgin male mice were purchased from 
Charles River Laboratories (Margate, Kent, UK; n=32). Mice had been maintained as 
homozygous WT and back-crossed more than 20 generations 
(https://www.criver.com/sites/default/files/Technical%20Resources/C57BL_6%20Mouse%20
Model%20Information%20Sheet.pdf). Mice were housed 4 per cage in sibling groups with 
identical enrichment and allocated to surgical groups based on cage number. Weight was 
monitored before and for 48 hours after surgery. Order of surgery was based on cage number 




For provocation of osteoarthritis by aging, WT 129/SV/C57BL/6J male mice (16 weeks and 1 
year of age, 12 total, 6 mice/group) were generated from a long-standing colony originally 
obtained from Jacques Samarut (École Normale Supérieure, Lyon, France)104. WT mice were 
maintained and back-crossed for more than 20 generations. 
 
Dio2 mutant mice 
Homozygous 16-week-old F3 male mice (19 mice total) in which the wild-type mouse 
deiodinase 2 (Dio2) allele at residue 92 (proline/proline) was replaced with human minor 
(alanine/alanine) or major (threonine/threonine) alleles by CRISPR/Cas9 (Dio2Ala92, n=9 and 
Dio2Thr92,  n=10) were previously generated by Applied Stemcell Inc. (Milpitas, CA, USA) and 
housed as described74. No previous drugs, tests or procedures were administered. Information 
regarding back-crossing status, weight, health status, husbandry and specific conditions 
(including housing, temperature, humidity and cage conditions) is available on request. 
 
Human sample collection 
The study design and conduct complied with all relevant regulations regarding the use of 
human study participants and were conducted in accordance to the criteria set by the 
Declaration of Helsinki. All patients provided written, informed consent prior to participation.  
Tissue samples were collected from 115 patients undergoing total joint replacement surgery 
in 4 cohorts: 12 knee osteoarthritis patients (cohort 1; 2 women, 10 men, age 50-88 years, 
mean 68 years); 20 knee osteoarthritis patients (cohort 2; 14 women, 6 men, age 54-82 years, 
mean 70 years); 13 hip osteoarthritis patients (cohort 3; 8 women, 5 men, age 44-84 years, 
mean 62 years); 70 knee osteoarthritis patients (cohort 4; 42 women, 28 men, age 38-84 
years, mean 70 years). Matched low-grade and high-grade cartilage samples were collected 
from each patient. This work was approved by Oxford NHS REC C (10/H0606/20 and 
15/SC/0132). Samples from knee osteoarthritis patients were collected under Human Tissue 
Authority license 12182, Sheffield Musculoskeletal Biobank, University of Sheffield, UK; 
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samples from hip osteoarthritis patients were collected under National Research Ethics 
approval reference 11/EE/0011, Cambridge Biomedical Research Centre Human Research 
Tissue Bank, Cambridge University Hospitals, UK.   
 
Rapid-throughput OBCD joint phenotyping 
Sample preparation 
Hindlimbs from WT and mutant mice were skinned and fixed for 24-30h in 10% neutral 
buffered-formalin, rinsed twice and stored in 70% ethanol at 4°C. Samples were anonymized 
and randomly assigned to batches for rapid-throughput analysis.  Prior to analysis, limbs were 
rehydrated in PBS + 0.02% sodium azide for >24h. Soft tissue was removed and the knee 
joint was disarticulated under a Leica MZ9 dissecting microscope (Leica Microsystems, UK) 
with the aid of fine forceps (Dumont #5, Cat#11252-20; Fine Science Tools, Germany) and 
5mm spring scissors (Vannas Tubingen, Cat#15003-08, Fine Science Tools, Germany). 
 
Iodine contrast-enhanced µCT 
This method was developed to detect signs of osteoarthritis, including cartilage damage and 
subchondral bone sclerosis or bone loss. The joint is immersed in an iodinated contrast agent 
with similar X-ray absorption to bone and imaged (Figure 2). This allows segmentation of both 
the articular cartilage and underlying subchondral bone in the same volume of interest. The 
technique can also be used to analyze the condyles and head of the femur. 
 
Rehydrated tibiae were blotted on low-linting tissue (Kimtech, UK) to remove all liquid. Single 
tibiae were placed into 6mm sample holders (Scanco Medical AG, Brüttisellen, Switzerland) 
in 180mg/mL ethiodized oil (Lipiodol Ultra, Guerbet Laboratories, Solihull, UK) mixed with 
sunflower oil. The tibial epiphysis (1-1.5mm) was scanned using a Scanco µCT-50 micro-
computerized tomography (µCT) scanner with X-ray tube potential 70 kVp, 200 μA tube 
current, 2µm voxel size with 1500ms integration time and 1x averaging. Documented quality 
control scans were performed routinely as indicated by the manufacturer and conform to 
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reporting recommendations105. Images were processed using the Scanco software (µCT 
Tomography v6.4-2/Open VMS), with Gaussian filtration (standard deviation, sigma; 0.8, 
support; 1), and component labelling for the 20 (subchondral bone) and 5 (articular cartilage) 
largest particles. A 3 voxel (subchondral bone) and 5 voxel (articular cartilage) dilation/erosion 
was applied. 
 
Analysis was performed using Xming 6.9.0.31 (©2005-2007 Colin Harrison) software 
implemented with the pUTTy client program (release 0.62 ©1997-2011 Simon Tatham).  
Tomographs were rotated twice to place the limb in a standard position. First, the tibia was 
rotated clockwise to point the anterior-most patellar surface vertically. Secondly, the tibia was 
rotated 90° to place the medial-lateral axis of the tibia facing the viewer (Figure 2a, coronal 
views). Medial and lateral tibial plateaux were analyzed separately. Equally sized medial and 
lateral VOIs were scaled automatically according to the size of the tibia (Figure 2a, medial-
lateral dimensions, a-b; anterior-posterior dimensions, c-d). The width of each VOI was equal 
to 14% of the medial-lateral axis, which equated to 59% of the medial plateau width and 53% 
of the lateral plateau width. The anterior-posterior dimension of each VOI was 33% of the size 
of each tibia. VOIs were located at the same positions on each limb by determining the plateau 
edges (Figure 2a; e, f, g, h). Each VOI was then centered on the medial-lateral midpoint of the 
plateau (Figure 2a, dashed line), and the lateral plateau VOI was further offset by a distance 
equivalent to 7% of the medial-lateral axis (Figure 2a). The medial VOI midpoint was 61.5%, 
and the lateral VOI midpoint 68.5% (7% posterior shift) along the anterior-posterior axis. This 
accounted for the different shapes of the medial and lateral plateau, based on standard 
measurements determined from mean values obtained from 10 wild-type mice to capture the 
thickest part of each plateau (Supplementary Data 13). 
 
For articular cartilage, all tissue below a density threshold of 200 mg hydroxyapatite/cubic 
centimeter (mg HA/cm3) was analyzed. The volume and thickness (median and maximum) 
were determined. For subchondral bone, all tissue between the articular cartilage and the 
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growth plate above a density threshold of 300 mg HA/cm3 was analyzed. Relative subchondral 
bone volume/tissue volume (BV/TV), tissue mineral density (TMD), trabecular thickness 
(Tb.Th) and trabecular number (Tb.N) were determined. Of note, the use of the Lipiodol 
contrast agent in ICEµCT results in a systematic and predictable increase in subchondral bone 
parameters (Supplementary Data 13). However, since all samples are processed and imaged 
identically this systematic increase does not compromise data interpretation as results 
represent relative comparisons.   
 
For osteophytes, coronal sections located at the midpoint of the VOI were scored for the 
presence or absence of osteophytes by 3 blinded independent scorers (Supplementary Figure 
3, Supplementary Data 2, 8).  
 
To validate ICEµCT, we compared the maximum cartilage thickness (Cg.Th) determined from 
OARSI histological sections with the same parameter determined by ICEµCT. We measured 
Cg.Th in ICEµCT images and histological sections from 23 samples that had undergone 
OBCD rapid-throughput joint phenotyping and histological analysis (samples obtained from 
sham-operated (n=3) and DMM-operated (n=3) 12-weeks after surgery at 22-weeks-of-age, 
wild-type mice at 16- (n=7) and 52- (n=6) weeks-of-age, Sh3bp4-/- (n=1), Pitx1-/- (n=2), 
Bhlhe40-/- (n=1) at 16-weeks-of-age). Linear regression was performed to determine the 
correlation between the two methods and Bland-Altman plots were generated83, 106. Maximum 
Cg.Th determined by the two techniques was strongly correlated (R2 = 0.91, MTP, P<0.0001, 
R2 = 0.755, LTP, P<0.0001, Supplementary Figure 10). Furthermore, there was no 
proportional bias in measurements, and no increase in differences between methods with 
phenotype severity (Bland-Altman plot; MTP; bias, -0.0002273mm, R2 = 0.125, P=0.106, LTP; 
bias, 0.004217mm, R2 = 0.011, P=0.63, Supplementary Figure 10). 
Nevertheless, the LTP Max Cg.Th was significantly thicker when measured by histology 
(mean value +4.4%) when compared to measurement by ICEµCT (*P=0.014) (Supplementary 
Figure 10e). To investigate this difference, we tested whether ICEµCT sample preparation 
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resulted in shrinkage.  However, ICEµCT analysis of fresh and fixed samples showed no 
significant difference in cartilage volume and thickness (Supplementary Figure 10f). Overall, 
these studies demonstrate an absence of shrinkage during ICEµCT sample preparation, but 
a consistent difference in Max Cg.Th observed in the LTP but not the MTP when comparing 
ICEµCT with histology.  These findings suggest a difference in anatomical orientation of the 
LTP relative to the MTP that is revealed when 2D (histology) and 3D (ICEµCT) imaging are 
compared.  We hypothesise that the apparent increase in LTP thickness determined by 
histology results from a horizontal anterior-posterior tilt in the LTP relative to the MTP, but this 
relative anatomical relationship does not affect the Max Cg.Th measured in 3 dimensions by 
ICEµCT. 
 
Joint surface replication 
This method was developed to determine articular cartilage surface damage. The technique 
enables visualization of joint surface morphology at high-resolution in the natural hydrated 
condition by using a resin cast as a surrogate (Figure 2b-c). The method can also be used to 
analyze the condyles and head of the femur. 
 
Moulding joint surface replicas 
Disarticulated, rehydrated tibiae were positioned with the articular surfaces parallel to the 
moulding surface using Draper Helping Hand brackets with articulated arms (31324Hh, 
Bamford Trading, Ross-on-Wye, UK). A multi-aperture moulding template of depth >0.5cm 
was custom-made. Moisture was removed to preserve surface detail by blotting with low-
linting tissue (Kimtech). Samples were immersed immediately in Virtual Light Body dental 
impression medium (Ivoclar-Vivadent, Leicester, UK) for 4 minutes prior to de-moulding and 
immediate return to storage medium. Moulds were visually inspected for defects or bubbles 




Casting joint surface replicas  
Joint surface replicas were cast using Crystal Clear 202 acrylic resin (Smooth-On, Bentley 
Advanced Materials, London, UK) according to manufacturer’s instructions (Figure 2). Pre-
warmed (37°C) parts A and B (1:9 ratio) were mixed thoroughly and vacuum de-gassed. Resin 
was poured into joint surface moulds by gravity flow using a fine pipette tip with the aid of a 
dissecting microscope (MZ9, Leica Microsystems, UK) and bubbles were removed from 
mould-resin interfaces. Casts were set for 16h at 18-23°C, post-cured for 6h at 65°C and 
removed from moulds after 7 days at room temperature, according to manufacturer’s 
instructions. Each cast was secured to a custom-produced 10x10x0.3cm aluminum raft with 
double-sided carbon tape (Agar Scientific, Stansted, UK). Rafts of samples were coated with 
>20nm carbon using a high-vacuum bench-top carbon coater (Agar Scientific). 
 
Imaging joint surface replicas 
Coated samples were analyzed using a Vega3 XMU scanning electron microscope (Tescan 
UK, Cambridge) at high vacuum with a 4-quadrant back-scattered electron detector (Deben, 
Bury St. Edmunds, UK). Tibial plateaux were imaged at 1536x1536 pixel image size with a 
scan speed of 5 and 3x frame-corrected averaging over a view field of 1800x1800µm (Figure 
2).  Beam voltage was 20kV and working distance was 17mm. ImageSnapper semi-automated 
imaging software (V1.0, Tescan UK) was used to acquire images. The presence or absence 
of osteophytes was determined by 3 blinded independent scorers (Supplementary Figure 3, 
Supplementary Data 2, 8). 
 
Damage quantitation in joint surface replicas  
A quantitation pipeline was developed to determine areas of damage on the joint surfaces of 
the medial and lateral plateau accurately, while excluding extraneous surface debris (Figure 
2c). Macros (ImageJ1.44) were produced for automated analysis (see below; Supplementary 
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Data 14). Samples were analyzed in batches by a blinded operator. After each step, macros 
included batch-saving of modified images, unless otherwise stated. Particle sizes are based 
on pixel size of 1.37µm2. Steps for semi-automated damage quantitation were: 
 
1) Select plateau (free select tool; Figure 2c, 2nd panel and close-up). Isolated plateaux were 
batch-saved with a modified file name (Macro 1; automated) 
2) Exclude bright outlier particles <4 pixels (5.5µm2; Macro 2; automated) 
3) Detect damage using the find edges tool (Macro 3, Figure 2c, 3rd panel and close-up; 
automated) 
4) Manually erase debris (soft tissue, bubbles in moulded surfaces) with close comparison to the 
original image and batch save with a modified file name (Macro 4; automated) 
5) Adjust the threshold to capture all damage accurately with close comparison to the original 
image and batch save with a modified file name (Macro 5, Figure 2c, 4th panel and close-up; 
automated) 
6) Quantify damage area (analyze particles tool; Macro 6, Figure 2c, 5th panel and close-up) 
particle size >20 pixels (27.5µm2), circularity 0-0.5 (0; line; 1; perfect circle). Excluding circular 
objects further refines the damage selection as circular objects are not likely to be genuine 
damage (automated) 
 
Damage area was recorded and represented as percentage of the total plateau area. The 
whole plateau area was determined by performing steps 1–2 above, and then: 
 
7) Set threshold to minimum and batch save with a modified file name (Macro 5; automated) 
8) Determine whole plateau area (analyze particles tool; Macro 6; plateau outline in Figure 2c, 5th 
panel), particle size >100 pixels (188µm2), circularity 0–1 (automated) 
 
Subchondral X-ray microradiography 
Quantitative subchondral X-ray microradiography (scXRM) was performed at 10µm pixel 
resolution using a Faxitron MX20 variable kV point-projection X-ray source and digital image 
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system (Qados, Cross Technologies plc, Berkshire, UK) with modifications to previously 
published protocols21, 22. The protocol is detailed in full below. 
 
Disarticulated tibiae were imaged flat with the posterior surface facing downwards (Figure 2d).  
Samples were imaged at 26 kV for 15s with the sample tray raised 6mm above the 5x 
magnification slot to maximize analysis area. Quantitation was performed in ImageJ1.44 by 
stretching pixel information between density values for plastic (minimum) and steel (maximum) 
standards and assigning to one of 256 bins using Macro 7 and automated batch saving 
(Supplementary Data 14). The width of each tibia at the growth plate was determined and 
used to automatically scale the regions of interest (ROIs; height: 9%, width: 34%, of the growth 
plate width). These dimensions were based on an optimal ROI size determined from 10 wild-
type tibiae that was sufficiently wide to include the whole subchondral plate and shallow 
enough to avoid calcified cartilage. The ROI positions were parallel to each plateau and 
included the topmost yellow pixel representing the bone directly beneath the tibial plateau. For 
each ROI, the number of pixels in each bin was determined using the Custom Histogram 
macro (http://rsb.info.nih.gov/ij/). The median grey level (density bin at which the cumulative 
frequency of pixels reaches 50%) defines the relative bone mineral content (BMC). BMC 
determined by scXRM correlated with BMC determined by ICEµCT (tissue mineral density 
multiplied by bone volume (TMD*BV) in 100 WT mice; LTP (R2=0.601, ***P=2.77x10-11) and 
MTP (R2=0.531, ***P=2.77x10-11; Supplementary Data 6).  
 
Repeatability and precision 
To determine the repeatability of each method, 7 wild-type samples were selected that were 
evenly distributed across the reference range. Samples were blinded and analyzed 5 times in 
a random order, and in a different random order for each method. Mean, standard error of the 
mean, absolute precision error [standard deviation; PE(SD)], and precision error as 
percentage of coefficient of variation [PE(%CV)]107 were calculated for each sample across 5 
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measurements (Supplementary Figure 1b and Supplementary Data 15). Results were also 
expressed as the number of standard deviations away from the reference range mean 
(Supplementary Data 15). The average precision error for each parameter was calculated 
using the root-mean-square107 (Supplementary Data 15). 
 
To determine whether the precision error of the methods increases with phenotype severity in 
mutants, we performed an additional repeatability analysis on a subset of 6 knockout mouse 
lines with a wide range of phenotype severities (Bhlhe40-/-, Gsdme-/-, Josd1-/-, Pitx1+-/-, Sh3bp4-
/- and Unk-/-). Samples were analysed in an identical manner to the wild-type cohort described 
above. Spearman correlations were calculated comparing phenotype severity with absolute 
precision error [PE(SD)] and with precision error as a percentage coefficient of variation 
[PE(%CV)]. Linear regression analysis demonstrated that precision error did not change with 
phenotype severity for 17/18 parameters. Nevertheless, the absolute precision error of MTP 
cartilage surface damage [Cg. Damage Area (%)] did increase with phenotype severity 
(R2=0.906, P=0.001; Supplementary Data 16).  
 
To assess repeatability of the methods in both wild-type and mutant cohorts, two-way mixed-
model intra-class correlation coefficients (single measure, absolute agreement) with 95% 
confidence intervals were calculated for repeated analyses by a single rater83, 108. All 
parameters had intra-class correlation coefficients >0.8, indicating excellent reproducibility 
(Supplementary Data 15). 
 
Surgical provocation of osteoarthritis 
Mice underwent destabilization of the medial meniscus (DMM)13, 24 osteoarthritis provocation 
surgery at 10 weeks-of-age. To minimize recovery time, mice were anaesthetized using 
inhaled isofluorane/oxygen mix (1-1.5L/min), and breathing rate was monitored visually 
throughout surgery. The medial meniscal-tibial ligament (MMTL) of the right knee was 
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transected using a 5mm microsurgical blade (World Precision Instruments, Hitchin, UK, Cat# 
500249). Sham surgery was performed on the left knee, in which skin and joint capsule were 
opened but the MMTL was left intact. Each joint capsule was closed with a single suture, and 
the skin was closed using intradermal sutures. Temperature was maintained using a heat-pad 
and monitored by rectal thermometer.  Post-operative buprenorphine (0.1mg/kg in saline, 
Vetergesic; Ceva United Kingdom, Amersham, UK), and carprofen (5mg/kg in saline, Rimadyl; 
Zoetis, Leatherhead, UK) were administered subcutaneously post-surgery while under 
anesthetic, and daily for 48h. Dosage was calculated based on individual weight. Physical 
pain indicators (including mobility, piloerection and hunching) were monitored post-surgery 
and daily for 48h. Surgeries were performed between 10am and 4pm in a designated surgical 
suite. Mice were returned to the home cage for recovery. Mice were housed 4 per cage in 
sibling groups and sacrificed 12 weeks post-surgery. 
 
Left and right hindlimbs from half of the experimental cohort (16 mice; 2 mice/cage) were 
phenotyped by rapid-throughput OBCD joint phenotyping. The limbs of the other half of the 
surgical cohort (2 mice/cage) were sectioned and scored for osteoarthritis using gold standard 
protocols. Numbers of mice in each group were based on group numbers in published 
guidelines24. 
 
Histological scoring of DMM surgical samples 
Articulated left (sham) and right (DMM) hindlimbs were decalcified for 7-10 days in 10% EDTA 
and embedded in paraffin wax in a 90° flexed physiological position. Coronal 4µm sections 
were cut at 80µm intervals through the knee joint and stained with Safranin O/Fast green and 
Weigert’s haematoxylin counterstain77, 109. Sections from 5 levels within the articulating zone 
centered around the midpoint were scored for each limb. All sections were scored by 3 blinded 
observers using the Osteoarthritis Research Society International (OARSI) scoring system23. 
Summed and maximum scores were calculated for each compartment (medial tibial plateau; 
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MTP, medial femoral condyle; MFC, lateral tibial plateau; LTP, lateral femoral condyle; LFC) 
in a single limb from 5 sections. In cases when 5 sections were not available, scores were 
weighted according to the following equation: 
 
(1)                     Weighted score = score + [(5-N) x (score/N)] 
 
where N was the number of scoreable sections. Weighted scores were rounded to the nearest 
0.5.  Sum scores represent the sum of scores from 5 levels. The maximum score is the highest 
score (out of a maximum of 6). The total joint sum score is the sum of scores for all 
compartments across 5 levels. The total joint maximum score represents the maximum score 
from all compartments across 5 levels. The presence of osteophytes was also scored 
(Supplementary Data 1). Lack of displacement of the medial meniscus was considered a 
criterion for exclusion (n=1 mouse). Synovitis severity was scored in the same sections 
[(severity score = sum of pannus formation score (0-3) + synovial lining hyperplasia score (0-
3) + sub-synovial inflammation score (0-3)]110, 111, 112. Five sections from each knee were 
scored by a blinded scorer. Differences between mean scores were evaluated by 2-tailed 
Wilcoxon matched-pairs signed rank tests (Supplementary Figure 3, Supplementary Data 17). 
 
Analysis of osteophytes 
We scored osteophytes by histology, ICEµCT and JSR in sham and DMM-operated limbs 12 
weeks after surgery at 22 weeks-of-age, and by ICEµCT and JSR in mutant mouse lines at 
16 weeks-of-age. In sham and DMM-operated limbs, the numbers of samples in which 
osteophytes were detected by ICEµCT and JSR did not differ from the number of samples in 
which osteophytes were detected by histology (P>0.9999; P=0.7874, Fisher’s exact test; 
Supplementary Data 2), indicating detection of osteophytes by ICEµCT and JSR is equivalent 
to detection by OARSI histology. A combination of ICEµCT and JSR is required for osteophyte 
 43
analysis in mutant mice, as JSR may not detect osteophytes in dysmorphic or severely 
damaged joints (Supplementary Data 8). 
 
Co-registration with gold standard histology 
To co-register data obtained from OBCD joint phenotype analysis directly with OARSI 
histological scoring, we performed further histology and OARSI scoring of samples from 3 
mice that had previously been phenotyped in the OBCD pipeline and found to have mild, 
intermediate and severe degrees of joint damage (Supplementary Figure 4). 4µm coronal 
sections were cut at 50µm intervals through the disarticulated tibiae and femora. Five sections 
centered around the midpoint of each femur and tibia were analysed by 3 independent scorers, 
and the mean summed and maximum scores determined. 
 
Functional genomics analysis of human cartilage 
We isolated chondrocytes from each cartilage sample as described113 and detailed in full in 
Supplementary Methods (see Supplementary Information). Assays and analyses were 
performed as described in Supplementary Methods (see Supplementary Information), and 
RNA sequencing was performed on the Illumina HiSeq2000 or Hiseq4000 (75bp paired-ends), 
with quality control including FastQC 0.11.5 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). For raw RNA sequencing data 
details see Data Availability Statement. For protein extracts, we carried out digestion, 6-plex 
or 10-plex tandem mass tag labelling and peptide fractionation. For samples from 12 knee 
osteoarthritis patients, we applied a liquid chromatography mass spectrometry (LC-MS) 
analysis using the Dionex Ultimate 3000 ultra-high-performance liquid chromatography 
(UHPLC) system coupled with the high-resolution LTQ Orbitrap Velos mass spectrometer 
(Thermo Fisher Scientific GmbH, Dreieich, Germany). For all remaining samples, LC-MS 
analysis was performed on the Dionex Ultimate 3000 UHPLC system coupled with the 
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Orbitrap Fusion Tribrid Mass Spectrometer (Thermo Fisher Scientific). For proteomics data 
details see Data Availability Statement. 
 
OBCD bone phenotyping 
Samples from 16-week-old female IMPC knockout mice were used to determine bone mass 
and strength parameters in the rapid-throughput OBCD bone phenotyping pipeline 16, 17, 19, 
and results are reported in Supplementary Data 7. Samples were stored in 70% ethanol, 
anonymized and randomly assigned to batches for rapid-throughput analysis. The relative 
BMC and length of the femur and caudal vertebrae were determined at 10μm pixel resolution 
by digital X-ray microradiography (Faxitron MX20). Micro-CT (Scanco µCT-50, 70kV, 200μA, 
0.5mm aluminum filter) was used to determine cortical bone parameters (thickness, BMD, 
internal diameter) at 10μm voxel resolution in a 1.5mm region centered on the mid-shaft region 
56% of the way along the length of the femur distal to the femoral head, and trabecular bone 
parameters (bone volume, trabecular number, thickness, spacing) at 5μm voxel resolution in 
a 1mm region beginning 100μm proximal to the distal growth plate. Biomechanical variables 
of bone strength and toughness (yield load, maximum load, fracture load, energy dissipated 
prior to fracture) were derived from destructive three-point bend testing of the femur and 
compression testing of caudal vertebrae 6 and 7 (Instron 5543 load frame, 100N and 500N 
load cells). Overall, 19 skeletal parameters were reported for each individual mouse studied 
and compared to reference data obtained from 320 16-week-old wild type female mice of 
identical genetic background.  
 
Prioritization pipeline 
A prioritization pipeline was developed based on the severity of the mutant mouse phenotype 
and i) additional skeletal abnormalities identified in mutant mice, ii) gene expression in skeletal 
cells and tissues, iii) gene association with human monogenic and complex diseases, and iv) 
structured literature searching (Supplementary Data 7). 
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Genes were allocated overall priority scores out of a total maximum of 21 as follows: 
 
A maximum score of 6 for rapid-throughput OBCD joint phenotyping (outlier according to 
criteria of reference range, Wilcoxon test followed by Bonferroni adjustment and Mahalanobis 
analysis, 1 point each; abnormal articular cartilage morphology, articular cartilage damage, 
subchondral bone morphology, 1 point each). 
 
A maximum score of 5 for abnormal skeletal phenotypes reported in genetically modified mice 
by other studies. The following resources were searched: 1) OBCD bone phenotype data, 2) 
International Mouse Phenotyping Resource of Standardized Screens (IMPReSS; 
https://www.mousephenotype.org/impress), 3) Deciphering the Mechanisms of 
Developmental Disorders database (DMDD; https://dmdd.org.uk/), 4) PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed/) using the search criteria “GENE NAME AND 
(knockout OR deletion OR mutation)”, and 5) Mouse Genome Informatics database 
(http://www.informatics.jax.org/). The presence of an abnormal skeletal phenotype was 
assigned 1 point per database. 
 
A maximum score of 4 for expression in skeletal tissues and cells (the skeleton, chondrocytes, 
osteoblasts/osteocytes and osteoclasts; Supplementary Data 7). Expression in the skeleton 
(1 point) was determined by searching MGI (http://www.informatics.jax.org/) and BioGPS 
(http://biogps.org/#goto=welcome). An expression level greater than the median was 
considered to indicate tissue or cell type expression. Expression in chondrocytes (1 point) was 
determined by searching published transcriptome data27 and SkeletalVis28 
(http://phenome.manchester.ac.uk/). Search was limited by species (human) in both datasets.  
In Kean et al.27 a baseMean expression greater than the median was considered to indicate 
cell type expression. In SkeletalVis searches, a fold-change greater than 2 (P<0.001) was 
considered to indicate cell type expression. Expression in osteoblasts and/or osteocytes (1 
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point) was determined by searching BioGPS, SkeletalVis, and osteocyte RNAseq data19. 
Expression in osteoclasts (1 point) was determined by searching BioGPS, human osteoclast 
RNAseq datasets, and SkeletalVis. A baseMean expression greater than the median was 
considered to indicate cell type expression. 
 
A maximum score of 4 for association with monogenic and polygenic skeletal disease 
(Supplementary Data 7). Monogenic disease association was determined by searching MGI 
for human-mouse disease association, and Online Mendelian Inheritance in Man (OMIM, 
https://www.omim.org/) by gene name (1 point). Polygenic disease association was assessed 
by searching the European Bioinformatics Institute Genome-wide Association Studies 
database (EBI GWAS Catalogue, https://www.ebi.ac.uk/gwas/) for association with arthritis 
and skeletal diseases (1 point each). 
 
A maximum score of 2 for publications related to skeletal tissues and cells (Supplementary 
Data 7). Systematic structured searches of PubMed and Google Scholar 
(https://scholar.google.co.uk/) were performed using the search string “GENE NAME AND 
(arthritis OR cartilage OR skeleton OR chondrocyte OR osteoblast OR osteocyte OR 
osteoclast)”. For PubMed results, the following scores were assigned: 0 (<1 publication), 0.5 
(1–24 publications), or 1 (>25 publications). For Google Scholar results, the following scores 
were assigned: 0 (<100 results), 0.5 (100-999 results), or 1 (>1000 results). 
 
Quantitation and statistical analysis 
Statistical details and results of experiments are included in the relevant results section, figure 
legends, Reporting Summary and below. For all experiments, n refers to biological replicates 
(number of mice or histological sections). Measurements were taken from distinct samples 




OBCD joint phenotyping 
Reference range data was calculated from 100 wild-type mice for each parameter, and the 
mean, standard deviation, median and percentiles determined (Supplementary Data 3). 
Frequency distribution of datasets was assessed by the Shapiro-Wilk normality test. 
Reference ranges 2 standard deviation above or below the mean (normally-distributed 
parameters), or between the 2.5th-97.5th percentiles (non-normally distributed parameters), 
were determined. An outlier was defined if the mean value of a phenotype parameter was 
outside the defined reference range. 
 
Normally distributed parameters were articular cartilage volume (LTP), maximum articular 
cartilage thickness (LTP), subchondral bone volume/tissue volume (LTP), subchondral 
trabecular thickness (LTP, MTP), subchondral trabecular number (LTP), subchondral tissue 
mineral density (LTP), and subchondral bone mineral content (LTP, MTP). Non-normally 
distributed parameters were articular cartilage volume (MTP), median articular cartilage 
thickness (LTP, MTP), maximum articular cartilage thickness (MTP), articular cartilage surface 
damage (LTP, MTP), subchondral bone volume/tissue volume (MTP), subchondral trabecular 
number (MTP) and subchondral tissue mineral density (MTP). 
 
To determine the statistical significance of outlier parameters identified relative to the 
reference range, we performed non-parametric 2-tailed Wilcoxon rank sum tests 
(Supplementary Data 5, wilcox.test function in R). For each parameter, this analysis calculated 
whether the distribution parameters in mutant samples was significantly different to the 
distribution of parameters in the 100-sample WT reference range. To account for multiple 
testing when defining statistical significance, we calculated the effective number of tests and 
then applied a Bonferroni correction as follows. Because several of the 18 phenotype 
parameters determined in the 100 WT mice used to calculate reference data were correlated 
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(Supplementary Data 6, *P<0.05), we first calculated the number of effective tests using WT 
data in R. We calculated the pairwise correlations between all 18 parameters and obtained 
eigenvalues of the correlation matrix using the eigen function in R. We then calculated the 
number of effective tests (Neff) as: 
 
𝑁 𝑁 𝐼 𝜆 1 ∗ 𝜆 1  
 
where N=18 is the number of parameters, and  denotes the eigenvalues, resulting in an 
effective Neff≤=8.8. Thus, applying a Bonferroni correction for the effective number of tests, 
statistical significance for the differences between WT reference data and results from each 
mutant mouse line was P<0.00568, with a second more stringent threshold of P<0.0001 also 
correcting for the number of mouse lines. For each of 18 parameters across the 50 mouse 
lines, differences between mutant and WT values were determined by 2-tailed Wilcoxon rank 
sum tests. 
 
Differences between young and old wild-type mice, and between Dio2Thr92 and Dio2Ala92 mice, 
were determined using unpaired 2-tailed t-tests or 2-tailed Wilcoxon rank sum tests. 
 
Differences between sham and DMM-operated limbs from the same mouse were determined 
using paired 2-tailed t-tests, or 2-tailed Wilcoxon matched-pairs signed rank tests. 
 
Differences between OARSI histology and synovitis scores in sections from sham and DMM-
operated knee joints were determined using paired 2-tailed Wilcoxon matched-pairs signed 
rank tests. Differences between OARSI histology scores of sections from young and aged 





To determine the sample size required, we determined coefficients of variation (CV, standard 
deviation/mean) for normally distributed parameters, and percentage median absolute 
deviation from the median (median absolute deviation from the median (MAD)/median) for 
non-normally distributed parameters (Supplementary Data 3). The effect size (d) was set at 
twice the standard deviation (σ) or half of the 95% range as a percentage of the median. To 
detect this effect size with 80% power, the number of mice per group (N) was determined by 
 
𝑁 2




where power index (Z1-α/2+Z1-β)2 is 7.85 for a power of 80%, with MAD replacing σ for non-
normally distributed parameters. Thus, 4 mice are required to detect an effect size of 2 
standard deviations at 80% power, and 6 mice at 95% power, for all parameters. For non-
parametric data, 1-4 mice are required, depending on the parameter, to detect an outlier 
phenotype lying outside the 95% confidence intervals of the reference range (Supplementary 
Data 3). Minimum detectable effect sizes for all parameters at 80%, 90% and 95% power are 
presented in Supplementary Data 18. 
 
Mahalanobis analysis 
Robust Mahalanobis distances114, 115 were determined to identify outliers in multivariate data. 
These distances measure how far each observation is from the center of a data cluster, taking 
into account the variances of the variables and the covariances of pairs of variables. Robust 
Mahalanobis distances (MDi) 
 
MD 𝑥 𝑇 𝑋 𝐶 𝑋 𝑥 𝑇 𝑋  
 
were calculated for each sample (represented by a vector of multivariate observations 𝑥 ). 




robust estimate of the covariance matrix. Under the assumption of multivariate normality, the 
distribution of 𝑀𝐷  is approximately chi-squared with p degrees of freedom (where p is the 
number of variables). This means that any observation 𝑥  with 𝑀𝐷 𝜒 ; .  can be 
considered an outlier. The assumption of multivariate normality was checked by plotting the 
ordered distances against the corresponding quantiles of an appropriate chi-squared 
distribution. Robust estimates of the mean and covariance matrix are used so that potential 
outliers are not masked. The masking effect, by which outliers do not necessarily have a large 
Mahalanobis distance, can be caused by a cluster of outliers that attract the mean and inflate 
the covariance in its direct. By using a robust estimate of the sample mean and covariance, 
the influence of these outliers is removed and the Mahalanobis distance is able to expose all 
outliers. The minimum volume ellipsoid method was used to calculate robust estimates of the 
mean and covariance matrix. Given n observations and p variables, the minimum volume 







h points of minimum volume. All multivariate analysis was conducted in R (R Project for 
Statistical Computing). Overall, a mouse line was defined to have an abnormal joint phenotype 
using this method only when 50% or more individual samples from that line were identified as 
outliers following Mahalanobis analysis. 
 
Analysis of RNA and protein in human tissue 
Full details of this analysis are described in the Supplementary Methods (see Supplementary 
Information). Briefly, gene-level RNA quantification was carried out using Salmon 0.8.2116 and 
tximport117. After quality control, we retained expression estimates for 15,249 genes with 
counts per million of 1 or higher in at least 40 cartilage samples (combining low-grade and 
(5) 
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high-grade), and matched low-grade and high-grade cartilage samples from 83 patients. To 
identify gene expression differences between high-grade and low-grade cartilage, we carried 
out multiple analyses using limma118, 119, DESeq2120 and edgeR121 with 5 different designs to 
account for potential confounders. This yielded 2557 genes with significant differential 
expression between low-grade and high-grade cartilage at 5% false discovery rate (FDR) 
across all 5 analysis designs and all 5 testing methods. 
 
To carry out protein identification and quantification, we submitted the mass spectra to 
SequestHT search in Proteome Discoverer 2.1 and searched all spectra against a UniProt 
fasta file that contained 20,165 reviewed human entries. After quality control, we retained 4801 
proteins that were quantified in at least 30% of samples, and matched low-grade and high-
grade cartilage samples from 99 patients. To account for protein loading, abundance values 
were normalized by the sum of all protein abundances in a given sample, then log2-
transformed and quantile normalised. An analysis for differential abundance was carried out 
using limma118 with 2016 proteins showing significant differences at 5% FDR. 
 
We used Ensembl38p10 to identify human orthologues for 50 mouse genes phenotyped by 
the OBCD joint phenotyping pipeline. We identified high-confidence one-to-one orthologues 
for 43/50 genes. 
 
Data Availability Statement 
Source data are provided with this paper. All datasets generated and/or analyzed during the 
current study are included in Supplementary and Source Data, and available from the 
corresponding authors on reasonable request or as detailed below. Figures 1, 3-7, and 
Supplementary Figures 1-8 and 10 have associated raw data (included in the Supplementary 
Data and Source Data). Additionally, raw RNA sequencing data have been deposited in the 
European Genome-Phenome Archive [EGA; https://ega-archive.org/) with the identifiers 
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EGAS00001002255, EGAD00001003355 (n=17), EGAD00001003354 (n=9), 
EGAD00001001331 (n=12). Proteomics data have been deposited in the PRoteomics 
IDEntifications database (PRIDE; https://www.ebi.ac.uk/pride/archive/) with the identifiers 
PXD006673, PXD00202014 and PDX014666, username: reviewer90654@ebi.ac.uk, 
password: AoeRBm3e). Public databases used in this study are: BioGPS 
(http://biogps.org/#goto=welcome), Deciphering the Mechanisms of Developmental Disorders 
database (DMDD; https://dmdd.org.uk/), European Mutant Mouse Archive (EMMA; 
https://www.infrafrontier.eu/), European Bioinformatics Institute Genome-wide Association 
Studies database (EBI GWAS Catalogue, https://www.ebi.ac.uk/gwas/), Google Scholar 
(https://scholar.google.co.uk/), International Mouse Phenotyping Resource of Standardized 
Screens (IMPReSS; https://www.mousephenotype.org/impress), Mouse Genome Informatics 
database (http://www.informatics.jax.org/), Online Mendelian Inheritance in Man (OMIM, 
https://www.omim.org/), PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) and SkeletalVis28 




Code generated during this project is provided as Supplementary Data 14 and in the public 
repository Github (https://github.com/Molendo/OBCD). Repository: Molendo. Project: OBCD 
(search term: Molendo/OBCD).   
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Supplementary References  
Reference range data for joint phenotype parameters 
a. Graphs showing articular cartilage (articular cartilage volume (Cg.V), median articular cartilage thickness
(Median Cg.Th), maximum articular cartilage thickness (Max Cg.Th), Cg. damage area) and subchondral
bone (subchondral bone volume per tissue volume (SC BV/TV), SC trabecular thickness (SC Tb.Th), SC
trabecular number (SC Tb.N), SC tissue mineral density (SC TMD), SC bone mineral content (SC BMC))
parameters in the lateral and medial tibial plateaux (LTP, MTP) of 16-week-old male WT mice (n=100). Black
dots: individual mice.
b. Repeatability of measurement for each parameter determined by five repeat analyses of seven samples
obtained from individual 16-week-old wild-type mice. Black symbols are repeat measures for each sample,
with mean ± standard error of the mean.
c. Repeatability of measurement for each parameter determined by five repeat analyses of six samples
obtained from individual 16-week-old mutant mice representing the full spectrum of phenotype severity. Black
symbols are repeat measures for each sample with mean ± standard error of the mean.
In a-c, grey boxes are reference ranges derived from 100 wild-type samples. For normally distributed 
parameters [Cg.V (LTP), Max Cg.Th (LTP), SC-BV/TV (LTP), SC Tb.Th (LTP, MTP), SC Tb.N (LTP), SC 
TMD (LTP), SC BMC (LTP, MTP)], reference range is 2 standard deviations above and below the mean 
(black line). For non-normally distributed parameters [Cg.V (MTP), Median Cg.Th (LTP, MTP), Max Cg.Th 
(MTP), Cg. Damage Area (LTP, MTP), SC-BV/TV (MTP), SC Tb.N (MTP), SC TMD (MTP)], reference range 
is the 2.5th-97.5th percentile, and black line is the median.  mm; millimeters, mg HA/cm3; milligrams of 
hydroxyapatite/cubic centimeter. Source data are provided as a Source Data file. 
Supplementary Figure 1
Supplementary Figure 2
Joint abnormalities following destabilization of the medial meniscus (DMM) surgery and severe early 
onset osteoarthritis in Pitx1+/- mice  
a. Graphs showing articular cartilage (articular cartilage volume (Cg.V), median articular cartilage thickness
(Median Cg.Th), maximum articular cartilage thickness (Max Cg.Th), Cg. damage area) and subchondral
bone (subchondral bone volume per tissue volume (SC BV/TV), SC trabecular thickness (SC Tb.Th), SC
trabecular number (SC Tb.N), SC tissue mineral density (SC TMD), SC bone mineral content (SC BMC))
parameters in the lateral and medial tibial plateaux (LTP, MTP) of sham and DMM-operated knees of wild
type (WT) mice 12 weeks after surgery (n=16). Paired data (sham versus DMM) are shown for each mouse.
*P<0.05, **P<0.01, 2-tailed Wilcoxon matched pairs signed rank test for Cg.V (MTP), Median Cg.Th (LTP,
MTP), Max Cg.Th (MTP), Cg. Damage Area (LTP, MTP), SC-BV/TV (MTP), SC Tb.N (MTP) and SC TMD
(MTP), or 2-tailed paired t-test for Cg.V (LTP), Max Cg.Th (LTP), SC-BV/TV (LTP), SC Tb.Th (LTP, MTP),
SC Tb.N (LTP), SC TMD (LTP), SC BMC (LTP, MTP). Cg.V (MTP): P=0.001312, Median Cg.Th (LTP):
P=0.021729, Max. Cg.Th (MTP): P=0.017334, Cg. Damage Area (LTP): P=0.013092, (MTP): P=0.000031,
SC BV/TV (MTP): P=0.000061, SC Tb.Th (MTP): P=0.000013, SC Tb.N (MTP): P=0.000031, SC BMC
(MTP): P=0.000477.
b. Graphs showing Osteoarthritis Research Society International (OARSI) histological scores in sham and
DMM-operated knees of WT mice 12 weeks after surgery (n=11). Parameters include the summed and
maximum scores on the LTP, lateral femoral condyle (LFC), MTP, medial femoral condyle (MFC), and
combined values for the total joint. *P<0.05, **P<0.01, 2-tailed Wilcoxon matched pairs signed rank test. Sum
OARSI scores: LTP: P=0.0469, MTP: P=0.000977, MFC: P=0.000977, total joint: P=0.000977. Max. OARSI
scores: MTP: P=0.000977, MFC: P=0.001953, total joint: P=0.001953.
c. Graphs showing articular cartilage and subchondral bone parameters in the LTP and MTP of 16-week-old
Pitx1+/- mice (n=7). Orange circles: individual mutant samples, black horizontal lines: sample mean. Grey
boxes: reference ranges derived from 100 wild-type samples. For normally distributed parameters [Cg.V
(LTP), Max Cg.Th (LTP), SC-BV/TV (LTP), SC Tb.Th (LTP, MTP), SC Tb.N (LTP), SC TMD (LTP), SC BMC
(LTP, MTP)], reference range is 2 standard deviations above and below the mean (dashed line). For non-
normally distributed parameters [Cg.V (MTP), Median Cg.Th (LTP, MTP), Max Cg.Th (MTP), Cg. Damage
Area (LTP, MTP), SC-BV/TV (MTP), SC Tb.N (MTP) SC TMD (MTP)], reference range is the 2.5th-97.5th
percentile, and dashed line is the median. *P<0.00568, **P<0.001, ***P<0.0001, Bonferroni-corrected 2-
tailed Wilcoxon rank sum test. Cg.V (LTP): P=0.00001, (MTP): P=0.00008, Median Cg.Th (LTP):  P=0.00001,
(MTP): P=0.00307 Max. Cg.Th (LTP): P=0.00001, (MTP): P=0.00319, Cg. Damage Area (LTP): P=0.00014
(MTP): P=0.00001. mm; millimeters, mg HA/cm3; milligrams of hydroxyapatite/cubic centimeter. Source data
are provided as a Source Data file.
Supplementary Figure 2
Synovitis and osteophyte formation in destabilization of the medial meniscus (DMM)-operated mice 
a. Example Safranin O/Fast green-stained coronal sections from sham and DMM-operated joints
demonstrating the signs of synovitis in the operated knee. Black boxes indicate regions of interest shown in
b and c.
b. Synovial hyperplasia (red arrow, 10/11 knees) and sub-synovial inflammation with new blood vessel
formation (green arrow, 8/11 knees) are shown in the DMM-operated knee.
c. Pannus formation (black arrow, 1/11 knee) in the DMM-operated knee.
d. Schematic representation of the mouse knee joint, red; cartilage, blue; bone, grey; soft tissue
e. Mean synovitis scores in the lateral and medial compartments of sham and DMM-operated knees (n=11,
**P= 0.0059, 2-tailed Wilcoxon matched-pairs signed rank test). Source data are provided as a Source Data
file.
f. Safranin O/Fast green-stained coronal sections from sham and DMM-operated joints showing osteophyte
formation (yellow box).
g. Iodine contrast-enhanced µCT (ICEµCT) images showing osteophyte formation (yellow box).
h. Joint surface replica (JSR) images showing osteophyte formation outlined in yellow. Scale bars = 500µm
(panels a, f, g, h), and 100µm (panels b, c).
Supplementary Figure 3
Supplementary Figure 4
Validation of imaging methods 
a. Iodine contrast enhanced CT images of medial tibial plateau articular cartilage (red) and
subchondral bone (blue) from 22-week-old wild type (WT) male mice 12 weeks after sham operation or
following destabilization of the medial meniscus (DMM) surgery that resulted in either mild, intermediate
or severe osteoarthritis (OA).
b. Back-scattered electron scanning-electron microscopy images of medial tibial plateau joint surface
replicas from sham and DMM-operated WT mice with mild, intermediate or severe OA.
c. X-ray microradiography images of proximal tibia and the medial tibial plateau subchondral bone
region of interest (dashed box) from sham and DMM-operated WT mice with mild, intermediate or
severe OA. Greyscale images are pseudocoloured according to a 16 colour look-up table in which low
bone mineral content (BMC) is yellow and high BMC is pink.
d. Coronal sections of medial tibial plateaux stained with Safranin-O/Fast green from three sham and
three DMM-operated WT mice with mild, intermediate or severe OA (Sections assessed at 5 levels
through each knee joint). Arrows indicate areas of cartilage damage. Scale bars = 100m (a, b, d) and
1mm (c).
e. Graphs showing articular cartilage (articular cartilage volume (Cg.V), median articular cartilage
thickness (Median Cg.Th), maximum articular cartilage thickness (Max Cg.Th) and Cg. damage area)
and subchondral bone (subchondral bone volume per tissue volume (SC BV/TV), SC trabecular
thickness (SC Tb.Th), SC trabecular number (SC Tb.N), SC tissue mineral density (SC TMD), SC bone
mineral content (SC BMC)) parameters together with summed and maximum Osteoarthritis Research
Society International (OARSI) histological scores on the medial tibial plateaux of sham and DMM-
operated knees from three mice with mild, intermediate and severe OA. Results from the entire cohort
in grey, with mild, intermediate and severe examples coloured according to key. mm; millimeters, mg
HA/cm3; milligrams of hydroxyapatite/cubic centimeter. Source data are provided as a Source Data file.
Supplementary Figure 4
Early onset osteoarthritis in Bhlhe40-/- and Sh3pb4-/- mutant mice 
a. Graphs showing articular cartilage (articular cartilage volume (Cg.V), median articular cartilage thickness
(Median Cg.Th), maximum articular cartilage thickness (Max Cg.Th) and Cg. damage area) and subchondral
bone (subchondral bone volume per tissue volume (SC BV/TV), SC trabecular thickness (SC Tb.Th), SC
trabecular number (SC Tb.N), SC tissue mineral density (SC TMD), SC bone mineral content (SC BMC))
parameters in the lateral and medial tibial plateaux (LTP, MTP) from 16-week-old Bhlhe40-/- mice (n=3).
b. Graphs showing articular cartilage and subchondral bone parameters in the LTP and MTP from 16-week-
old Sh3pb4-/- mice (n=5).  Orange circles: individual mutant samples, black horizontal lines: sample mean.
Grey boxes: reference ranges derived from 100 wild-type samples. For normally distributed parameters [Cg.V
(LTP), Max Cg.Th (LTP), SC-BV/TV (LTP), SC Tb.Th (LTP, MTP), SC Tb.N (LTP), SC TMD (LTP), SC BMC
(LTP, MTP)], reference range is 2 standard deviations above and below the mean (dashed line). For non-
normally distributed parameters [Cg.V (MTP), Median Cg.Th (LTP, MTP), Max Cg.Th (MTP), Cg. Damage
Area (LTP, MTP), SC-BV/TV (MTP), SC Tb.N (MTP), SC TMD (MTP)], reference range is the 2.5th-97.5th
percentile, and dashed line is the median. *P<0.00568, **P<0.001, Bonferroni-corrected 2-tailed Wilcoxon
rank sum test. Bhlhe40-/-: Median Cg.Th (LTP): P=0.00469, Max. Cg.Th (LTP): P=0.00347, Max. Cg.Th
(MTP): P=0.00498. Sh3bp4-/-: Cg.V (LTP): P=0.00311, Median Cg.Th (LTP): P=0.00081. Max. Cg.Th (LTP):
P=0.00133, Cg. Damage Area (LTP): P=0.00282. mm; millimeters, mg HA/cm3; milligrams of
hydroxyapatite/cubic centimeter. Source data are provided as a Source Data file.
Supplementary Figure 5
Supplementary Figure 6
Early onset osteoarthritis in mice with deletion of genes differentially expressed in human 
osteoarthritis cartilage 
a. Graphs showing articular cartilage (articular cartilage volume (Cg.V), median articular cartilage thickness
(Median Cg.Th), maximum Cg.Th (Max Cg.Th), Cg. damage area) and subchondral bone (subchondral bone
volume per tissue volume (SC BV/TV), SC trabecular thickness (SC Tb.Th), SC trabecular number (SC Tb.N),
SC tissue mineral density (SC TMD), SC bone mineral content (SC BMC)) parameters in the lateral and
medial tibial plateaux (LTP, MTP) of 16-week-old Unk -/- mice (n=4).
b. Graphs showing articular cartilage and subchondral bone parameters in the LTP and MTP of 16-week-old
Josd1-/- mice (n=6).
c. Graphs showing articular cartilage and subchondral bone parameters in the LTP and MTP of 16-week-old
Gsdme-/- mice (n=4). Orange circles: individual mutant samples, black horizontal lines: sample mean. Grey
boxes: reference ranges derived from 100 wild-type samples. For normally distributed parameters [Cg.V
(LTP), Max Cg.Th (LTP), SC-BV/TV (LTP), SC Tb.Th (LTP, MTP), SC Tb.N (LTP), SC TMD (LTP), SC BMC
(LTP, MTP)], reference range is 2 standard deviations above and below the mean (dashed line). For non-
normally distributed parameters [Cg.V (MTP), Median Cg.Th (LTP, MTP), Max Cg.Th (MTP), Cg. Damage
Area (LTP, MTP), SC-BV/TV (MTP), SC Tb.N (MTP), SC TMD (MTP)], reference range is the 2.5th-97.5th
percentile, and dashed line is the median. *P<0.00568, Bonferroni-corrected 2-tailed Wilcoxon rank sum test.
Unk-/-: Cg.V (LTP): P=0.00215, Max Cg.Th (MTP): P=0.00295. Josd-/-: Median Cg.Th (LTP): P=0.00344,
(MTP): P=0.00487, Max Cg.Th (LTP): P=0.00362, Cg. Damage area (LTP): P=0.00563. Gsdme-/-: Cg.
Damage Area (LTP): P=0.00355. mm; millimeters, mg HA/cm3; milligrams of hydroxyapatite/cubic centimeter.
Source data are provided as a Source Data file.
Supplementary Figure 6
Age-related joint degeneration 
Graphs showing articular cartilage (articular cartilage volume (Cg.V), median articular cartilage thickness 
(Median Cg.Th), maximum Cg.Th (Max Cg.Th), Cg. damage area) and subchondral bone (subchondral bone 
volume per tissue volume (SC BV/TV), SC trabecular thickness (SC Tb.Th), SC trabecular number (SC Tb.N), 
SC tissue mineral density (SC TMD), SC bone mineral content (SC BMC)) parameters in the lateral and 
medial tibial plateaux (LTP, MTP) of 4-month-old (n=6) and 12-month-old (n=6) WT mice. *P<0.05, **P<0.01, 
2-tailed Wilcoxon rank sum test for Cg.V (MTP), Median Cg.Th (LTP, MTP), Max Cg.Th (MTP), Cg. Damage
Area (LTP, MTP), SC-BV/TV (MTP), SC Tb.N (MTP) and SC TMD (MTP), or 2-tailed t-test for Cg.V (LTP),
Max Cg.Th (LTP), SC-BV/TV (LTP), SC Tb.Th (LTP, MTP), SC Tb.N (LTP), SC TMD (LTP) and SC BMC
(LTP, MTP). Cg. Damage Area (LTP): P=0.002, (MTP):  P=0.026, SC BV/TV (LTP): P=0.008, SC Tb.Th
(LTP): P=0.039, SC Tb.N (LTP): P=0.035, SC BMC (MTP): P=0.034. mm; millimeters, mg HA/cm3; milligrams
of hydroxyapatite/cubic centimeter. Source data are provided as a Source Data file.
Supplementary Figure 7
Mice with a Dio2Ala92 polymorphism are protected from osteoarthritis 
Graphs showing articular cartilage (articular cartilage volume (Cg.V), median articular cartilage thickness 
(Median Cg.Th), maximum articular cartilage thickness (Max Cg.Th), Cg. damage area) and subchondral 
bone (subchondral bone volume per tissue volume (SC BV/TV), SC trabecular thickness (SC Tb.Th), SC 
trabecular number (SC Tb.N), SC tissue mineral density (SC TMD), SC bone mineral content (SC BMC)) 
parameters in the lateral and medial tibial plateaux (LTP, MTP) from 16-week-old Dio2Thr92 (n=9) and Dio2Ala92 
(n=10) mice. *P<0.05, **P<0.01, 2-tailed Wilcoxon rank sum test for Cg.V (MTP), Median Cg.Th (LTP, MTP), 
Max Cg.Th (MTP), Cg. Damage Area (LTP, MTP), SC-BV/TV (MTP), SC Tb.N (MTP) and SC TMD (MTP), 
or 2-tailed t-test for Cg.V (LTP), Max Cg.Th (LTP), SC-BV/TV (LTP), SC Tb.Th (LTP, MTP), SC Tb.N (LTP), 
SC TMD (LTP), SC BMC (LTP, MTP). Cg.V (MTP): P=0.019, Median Cg.Th (MTP): P=0.006, Cg. Damage 
Area (LTP): P=0.043, (MTP): P=0.016. mm; millimeters, mg HA/cm3; milligrams of hydroxyapatite/cubic 
centimeter. Source data are provided as a Source Data file. 
Supplementary Figure 8
Origins of Bone and Cartilage Disease (OBCD) rapid-throughput joint phenotyping compared to 
Osteoarthritis Research Society International (OARSI) histological scoring  
a. Timeline showing number of days and number of samples and images analysed for OBCD rapid-
throughput joint phenotyping of 12 mutant mouse lines (n=3 mice required per line).
b. Timeline showing number of days and number of samples and histological sections analysed for
phenotyping 12 mutant mouse lines by gold-standard OARSI scoring (n=12 mutant and 12 wild type mice
required per line).
Supplementary Figure 9
Validation of iodine contrast-enhanced µCT (ICEµCT) 
a. Maximum cartilage thickness (max. Cg.Th, mm) determined by ICEµCT versus maximum cartilage 
thickness determined by histology (mm). Lateral tibial plateau (LTP); medial tibial plateau (MTP); linear 
regression and 95% confidence intervals.
b. Correlation (R2) between cartilage thickness determined by ICEµCT and histology.
c. Bland-Altman plots comparing maximum cartilage thickness determined by ICEµCT versus histology. 
Linear regression and 95% limits of agreement are shown.
d. Table demonstrating that Bland-Altman analysis does not deviate from zero.
e. Max Cg.Th is significantly larger when measured by histology than when measured by ICEμCT, for LTP 
only (P=0.014, paired 2-tailed  t-test assuming unequal variance, *P<0.05).
f. Articular cartilage volume (Cg.V) and Max Cg.Th in  samples under ICEμCT conditions (fixation in 10% 
neutral buffered formalin, stored in 70% ethanol, rehydrated 24-36h in phosphate buffered saline) are not 
significantly different from that of unfixed cartilage (Bonferroni-corrected P-value *P<0.017). Cg.V (LTP): 
P=0.705, (MTP): P=0.500, Max. Cg.Th (LTP): P=0.0189, (MTP): P=0.135. mm; millimeter. Source data are 




Supplementary Methods  
Isolation of chondrocytes 
For cohorts 1-2, the isolation of chondrocytes has been described previously1 and the 
same protocol was followed for cohort 4. The protocol is described below. 
Osteochondral samples were transported in Dulbecco's modified Eagle's medium 
(DMEM)/F-12 (1:1) (Life Technologies) supplemented with 2mM glutamine (Life 
Technologies), 100U/mL penicillin, 100μg/mL streptomycin (Life Technologies), 
2.5μg/mL amphotericin B (Sigma-Aldrich) and 50μg/mL ascorbic acid (Sigma-Aldrich) 
(serum-free media). Half of each sample was then taken forward for chondrocyte 
extraction. Cartilage was removed from the bone, dissected and washed twice in 
1xPBS. Tissue was digested in 3mg/mL collagenase type I (Sigma-Aldrich) in serum-
free media overnight at 37°C on a flatbed shaker. The resulting cell suspension was 
passed through a 70μm cell strainer (Fisher Scientific) and centrifuged at 400g for 10 
minutes. Subsequently, the cell pellet was washed twice in serum-free media and 
centrifuged at 400g for 10 minutes. The resulting cell pellet was resuspended in 
serum-free media. Cells were counted using a haemocytometer and the viability 
checked using trypan blue exclusion (Invitrogen). The optimal cell number for spin 
column extraction from cells was between 4x106 and 1x107. Cells were then pelleted 
and homogenized. 
 
For cohort 3, the extraction of chondrocytes has previously been described2. The 
protocol was based on that for cohorts 1, 2 and 4 above, and is highly similar, with 
differences summarized in the following. Each cartilage portion was minced with a 
scalpel and placed in 20mL of Dulbecco’s modified Eagle medium (Invitrogen) 
containing 10% foetal bovine serum (Invitrogen) and 6mg/mL collagenase A (Sigma). 
 
 
The tissue culture flasks were incubated overnight to digest the cartilage pieces. The 
resulting cell suspension was passed through a 30μm filter (Miltenyi) and centrifuged 
at 400g for 10 minutes. The cell pellet was then re-suspended in 1mL of PBS and 
counted on a haemocytometer following 1:1 mixing with trypan blue to determine cell 
viability. 
 
DNA, RNA and protein extraction 
DNA, RNA, and protein extraction was carried out using Qiagen AllPrep 
DNA/RNA/Protein Mini Kit following manufacturer’s instructions. For cohort 3, minor 
modifications were made to the approach as previously described2 and the protocol is 
summarized below. Cells were lysed in 350µL RLT buffer containing 3.5µL β-
mercaptoethanol and centrifuged in a Qiashredder column (Qiagen) for 2min at 
20,800g. RNA, DNA and protein were purified using a series of column based 
centrifugation steps and RNA was eluted in 34µL RNase-free water, DNA in 100µL 
EB buffer and the protein pellet solubilized in 100µL 10% sodium dodecyl sulphate in 
PBS. DNA and RNA preparations were re-precipitated to remove buffer salts, and to 
concentrate the final product 20µL 3M sodium acetate, pH 5.5 (Ambion) was added 
per 100µL of DNA or RNA solution and mixed gently. Then, 283µL of molecular grade 
ethanol (Sigma) was added per 100µL of DNA or RNA solution to precipitate the 
nucleic acids and the mixture placed at -20C overnight. Samples were centrifuged at 
20,800g for 30 minutes and the supernatant removed, the pellet was washed with 
900µL 70% ethanol and the nucleic acids re-pelleted by spinning at 20,800g for 10 
minutes. Nucleic acids were resuspended in 32µL DNase/RNase free water. Samples 





We purified poly-A tailed RNA (mRNA) from total RNA using Illumina's TruSeq RNA 
Sample Prep v2 kits. We then fragmented the mRNA using metal ion-catalyzed 
hydrolysis and synthesized a random-primed cDNA library. The resulting double-
strand cDNA was used as the input to a standard Illumina library prep, whereby ends 
were repaired to produce blunt ends by a combination of fill-in reactions and 
exonuclease activity. We performed A-tailing to allow samples to be pooled, by adding 
an “A” base to the blunt ends and ligation to Illumina Paired-end Sequencing adapters 
containing unique index sequences. Due to better performance, the 10-cycle PCR 
amplification of libraries was carried out using KAPA Hifi Polymerase. A post-PCR 
Agilent Bioanalyzer was used to quantify samples, followed by sample pooling and 
size-selection of pools using the LabChip XT Caliper. The multiplexed libraries were 
sequenced on the Illumina HiSeq 2000 for cohort 1 and HiSeq 4000 for cohorts 2-4 
(75bp paired-ends). Sequenced data underwent initial analysis and quality control on 
reads as standard. This yielded gene expression data for samples from 110 patients. 
 
Proteomics 
Proteomics analysis was performed on cartilage samples from 103 patients. For 
cohort 1, all steps of protein digestion, 6-plex TMT labelling, peptide fractionation and 
LC-MS analysis on the Dionex Ultimate 3000 UHPLC system coupled with the high-
resolution LTQ Orbitrap Velos mass spectrometer (Thermo Scientific), were previously 
described1 and details are given below. The sample preparation protocol formed the 
basis of processing for cohorts 2-4 using 10-plex TMT labelling and an Orbitrap Fusion 
Tribrid Mass Spectrometer (Thermo Scientific) with otherwise only minor alterations, 
as described below. 
 
 
Proteomics: Cohort 1 
Protein digestion and TMT labeling 
The protein content of each sample was precipitated by the addition of 30μL TCA 8M 
at 4°C for 30 min. The protein pellets were washed twice with ice cold acetone and 
finally re-suspended in 40μL 0.1M triethylammonium bicarbonate, 0.05% SDS with 
pulsed probe sonication. Protein concentration was measured with Quick Start 
Bradford Protein Assay (Bio-Rad) according to manufacturer’s instructions. Aliquots 
containing 30μg of total protein were prepared for trypsin digestion. Cysteine disulfide 
bonds were reduced by the addition of 2μL 50mM tris-2-carboxymethyl phosphine 
(TCEP) followed by 1h incubation in a heating block at 60°C. Cysteine residues were 
blocked by the addition of 1μL 200mM freshly prepared Iodoacetamide (IAA) solution 
and 30min incubation at room temperature in the dark. Trypsin (Pierce, MS grade) 
solution was added to a final concentration 70ng/μL to each sample for overnight 
digestion. After proteolysis the peptide samples were diluted to 100μL with 0.1M TEAB 
buffer. A 41μL volume of anhydrous acetonitrile was added to each TMT 6-plex 
reagent (Thermo Scientific) vial and after vortex mixing the content of each TMT vial 
was transferred to each sample tube. Labeling reaction was quenched with 8μL 5% 
hydroxylamine for 15 min after 1h incubation at room temperature. Samples were 
pooled and the mixture was dried with SpeedVac concentrator and stored at -20°C 
until high-pH Reverse Phase (RP) fractionation. 
Peptide fractionation  
Offline peptide fractionation based on high pH Reverse Phase (RP) chromatography 
was performed using the Waters, XBridge C18 column (2.1 x 150mm, 3.5μm, 120Å) 
on a Dionex Ultimate 3000 HPLC system equipped with autosampler. Mobile phase 
(A) was composed of 0.1% ammonium hydroxide and mobile phase (B) was 
 
 
composed of 100% acetonitrile, 0.1% ammonium hydroxide. The TMT labelled peptide 
mixture was reconstituted in 100μL mobile phase (A), centrifuged and injected for 
fractionation. The multi-step gradient elution method at 0.2mL/min was as follows: for 
5 minutes isocratic at 5% (B), for 35min gradient to 35% (B), gradient to 80% (B) in 
5min, isocratic for 5minutes and re-equilibration to 5% (B). Signal was recorded at 
280nm and fractions were collected in a time-dependent manner every one minute. 
The collected fractions were dried with SpeedVac concentrator and stored at -20°C 
until LC-MS analysis. 
LC-MS analysis 
LC-MS analysis was performed on the Dionex Ultimate 3000 UHPLC system coupled 
with the high-resolution LTQ Orbitrap Velos mass spectrometer (Thermo Scientific). 
Each peptide fraction was reconstituted in 40μL 0.1% formic acid and a volume of 
10μL was loaded to the Acclaim PepMap 100, 100μm × 2cm C18, 5μm, 100Ȧ trapping 
column with a user modified injection method at 10μL/min flow rate. The sample was 
then subjected to a multi-step gradient elution on the Acclaim PepMap RSLC (75μm 
× 50cm, 2μm, 100Å) C18 capillary column (Dionex) retrofitted to an electrospray 
emitter (New Objective, FS360-20-10-N-20-C12) at 45°C. Mobile phase (A) was 
composed of 96% H2O, 4% DMSO, 0.1% formic acid and mobile phase (B) was 
composed of 80% acetonitrile, 16% H2O, 4% DMSO, 0.1% formic acid. The gradient 
separation method at flow rate 300nL/min was as follows: for 95min gradient to 45% 
B, for 5min up to 95% B, for 8min isocratic at 95% B, re-equilibration to 5% B in 2min, 
for 10min isocratic at 5% B.  
The ten most abundant multiply charged precursors within 380-1500m/z were selected 
with FT mass resolution of 30,000 and isolated for HCD fragmentation with isolation 
 
 
width 1.2Th. Normalized collision energy was set at 40 and the activation time was 
0.1ms for one microscan. Tandem mass spectra were acquired with FT resolution of 
7,500 and targeted precursors were dynamically excluded for further isolation and 
activation for 40 seconds with 10ppm mass tolerance. FT max ion time for full MS 
experiments was set at 200ms and FT MSn max ion time was set at 100ms. The AGC 
target vales were 3×106 for full FTMS and 1×105 for MSn FTMS. The DMSO signal at 
m/z 401.922718 was used as a lock mass. 
 
Proteomics: Cohorts 2-4 
Protein digestion and TMT labeling 
The protein content of each sample was precipitated by the addition of 30μL TCA 8M 
at 4°C for 30min. The protein pellets were washed twice with ice cold acetone and 
finally re-suspended in 40μL 0.1M triethylammonium bicarbonate, 0.1% SDS with 
pulsed probe sonication. Equal aliquots containing at least 10μg of total protein were 
reduced with 5mM TCEP for 1h at 60°C, alkylated with 10mM Iodoacetamide and 
subjected to overnight trypsin (70ng/μL) digestion. TMT 10-plex (Thermo Scientific) 
labelling was performed according to manufacturer’s instructions at equal amounts of 
tryptic digests. Samples were pooled and the mixture was dried with SpeedVac 
concentrator and stored at -20°C until peptide fractionation.  
 
Peptide fractionation 
Offline peptide fractionation was based on high pH Reverse Phase (RP) 
chromatography using the Waters, XBridge C18 column (2.1 x 150mm, 3.5μm) on a 
Dionex Ultimate 3000 HPLC system. Mobile phase A was 0.1% ammonium hydroxide 
and mobile phase B 100% acetonitrile, 0.1% ammonium hydroxide. The TMT labelled 
 
 
peptide mixture was dissolved in 100μL mobile phase A, centrifuged and injected for 
fractionation. The gradient elution method at 0.2mL/min included the following steps: 
5 minutes isocratic at 5% B, for 35 min gradient to 35% B, gradient to 80% B in 5 min, 
isocratic for 5 minutes and re-equilibration to 5% B. Signal was recorded at 280nm 
and fractions were collected every one minute. For cohort 4, peptide fractionation was 
performed on reversed-phase OASIS HLB cartridges at high pH and up to 9 fractions 
(10-25% acetonitrile elution steps) were collected for each set. The collected fractions 
were dried with SpeedVac concentrator and stored at -20°C until LC-MS analysis. 
 
LC-MS analysis   
LC-MS analysis was performed on the Dionex Ultimate 3000 UHPLC system coupled 
with the Orbitrap Fusion Tribrid Mass Spectrometer (Thermo Scientific). Each peptide 
fraction was reconstituted in 40μL 0.1% formic acid and a volume of 7μL was loaded 
to the Acclaim PepMap 100, 100μm × 2cm C18, 5μm, 100Ȧ trapping column with the 
μLPickUp mode at 10μL/min flow rate. The sample was then analysed with a gradient 
elution on the Acclaim PepMap RSLC (75μm × 50cm, 2μm, 100Å) C18 capillary 
column retrofitted to an electrospray emitter (New Objective, FS360-20-10-D-20) at 
45°C. Mobile phase A was 0.1% formic acid and mobile phase B was 80% acetonitrile, 
0.1% formic acid. The gradient method at flow rate 300nL/min was: for 90min gradient 
to 38% B, for 5min up to 95% B, for 13min isocratic at 95% B, re-equilibration to 5% B 
in 2min, for 10min isocratic at 10% B. Precursors were selected with 120k mass 
resolution, AGC 3×105 and IT 100ms in the top speed mode within 3sec and were 
targeted for CID fragmentation with quadrupole isolation width 1.2Th. Collision energy 
was set at 35% with AGC 1×104 and IT 35ms. MS3 quantification spectra were 
acquired with further HCD fragmentation of the top 10 most abundant CID fragments 
 
 
isolated with Synchronous Precursor Selection (SPS) excluding neutral losses of 
maximum m/z 18. Iontrap isolation width was set at 0.7Th for MS1 isolation, collision 
energy was applied at 55% and the AGC setting was at 6×104 with 100ms IT. The 
HCD MS3 spectra were acquired within 110-400m/z with 60k resolution. Targeted 
precursors were dynamically excluded for further isolation and activation for 45 
seconds with 7ppm mass tolerance. Cohort 4 was analyzed at the MS2 level with a 
top15 HCD method (CE 40%, 50k resolution) and a maximum precursor intensity 
threshold of 5×107 using the same MS1 parameters as above in a 360min gradient. 
 
Quantification of RNA levels 
We used samtools v1.3.13 and biobambam v0.0.1914 to convert cram to fasq files after 
exclusion of reads that failed QC. We applied FastQC v0.11.5 to check sample quality5 
and excluded 7 samples.  
 
We obtained transcript-level quantification using salmon 0.8.26 (with --gcBias and --
seqBias flags to account for potential biases) and the GRCh38 cDNA assembly 
release 87 downloaded from Ensembl [http://ftp.ensembl.org/pub/release-
87/fasta/homo_sapiens/cdna/]. We used tximport7 to convert transcript-level to gene-
level scaled transcripts per million (TPM) estimates, with estimates for 39,037 genes 
based on Ensembl gene IDs.  
 
We excluded 4 samples due to low mapping rate (<80%), 8 samples due to non-
European ancestry, 15 samples due to low RIN (<5), 3 samples due to abnormal gene 




The final gene expression dataset included 87 patients’ low-grade and 95 high-grade 
cartilage samples with 15,249 genes that showed counts per million (CPM) of 1 in 
40 samples (matched low-grade and high-grade samples from 83 patients).  
 
Quantification of protein levels 
To carry out protein identification and quantification, we submitted the mass spectra 
to SequestHT search in Proteome Discoverer 2.1. The precursor mass tolerance was 
set at 30ppm (Orbitrap Velos data, cohort 1) or 20ppm (Fusion data, cohorts 2-4). For 
the CID spectra, we set the fragment ion mass tolerance to 0.5Da; for the HCD 
spectra, to 0.02Da. Spectra were searched for fully tryptic peptides with maximum 2 
miss-cleavages and minimum length of 6 amino acids. We specified static 
modifications as TMT-6-plex at N-terminus, K and Carbamidomethyl at C; dynamic 
modifications included deamidation of N,Q and oxidation of M. For each peptide, we 
allowed for a maximum two different dynamic modifications with a maximum of two 
repetitions. We used the Percolator node to estimate peptide confidence. We set the 
peptide false discovery rate (FDR) at 1% and based validation on the q-value and 
decoy database search. We searched all spectra against a UniProt fasta file that 
contained 20,165 reviewed human entries. The Reporter Ion Quantifier node included 
a TMT-6-plex (Velos data, cohort 1) or TMT-10-plex (Fusion data, cohorts 2-4) custom 
Quantification Method with integration window tolerance at 20ppm or 15ppm, 
respectively. As integration methods, we used the Most Confident Centroid at the MS2 





We excluded samples from 4 patients due to non-European ancestry. The final dataset 
included low-grade and high-grade cartilage samples each from 99 patients, with 
4,801 proteins observed in 30% of samples, and 1,677 proteins in all samples, in line 
with the resolution depth of the isobaric labelling method employed. To account for 
protein loading, abundance values were normalized by the sum of all protein 
abundances in a given sample, then log2-transformed and quantile normalized. 
 
Differential RNA expression between high-grade and low-grade cartilage 
We tested differential expression of 15,249 genes between high-grade and low-grade 
cartilage using paired samples from 83 patients. To detect robust gene expression 
differences, we carried out analyses using different software packages as 
recommended in a landmark survey of best practices8, applying limma9, edgeR10, and 
DESeq211. We also tested 5 analysis designs with different options to account for 
technical variation, including SVAseq12. In particular, we tested for differential 
expression using:  
1) A paired analysis of intact and degraded samples (i.e. specifying patient ID 
as covariate) 
2) A paired analysis of intact and degraded samples, with 10 additional 
covariates accounting for technical variation identified by SVAseq12  
3) A paired analysis of intact and degraded samples, with 10 RNA sequencing 
batches as covariates 
4) An unpaired analysis of intact and degraded samples 
5) An unpaired analysis of intact and degraded samples, with 19 additional 




We tested for differential expression using the following R packages: 
I. Limma9 (with lmFit and eBayes), after applying limma-voom13 to remove 
heteroscedasticity 
II. DESeq211, separately with and without outlier filtering/replacement 
(minReplicatesForReplace=Inf, cooksCutoff=FALSE options) 
III. EdgeR10, using the likelihood ratio test (glmFit and glmLRT functions), and 
separately, using the F test (glmQLFit and glmQLFTest functions) 
 
Here and elsewhere, we used Ensembl38p10 to identify genes with uniquely 
corresponding Ensembl gene ID and gene name (13,737 of 15,249 genes in the RNA 
data).  
 
In each analysis design and method, we used a 5% False Discovery Rate (FDR) 
threshold to correct for multiple testing. As the final step, we applied a conservative 
approach and considered a gene “significantly differentially expressed” between low-
grade and high-grade cartilage if it showed significant differential expression across 
all analysis designs and testing methods (2,557 genes, including 2,418 with uniquely 
corresponding Ensembl gene ID and gene name).  
 
Differential protein abundance between high-grade and low-grade cartilage 
We performed differential analysis for 4,801 proteins that were measured in 30% of 
patients, applying limma9 to paired samples from 99 patients. Significance was defined 
at 5% FDR to correct for multiple testing, yielding 2,233 proteins with significant 
differential abundance (2,019 proteins with uniquely corresponding Ensembl gene ID 




As batch effects in proteomics data can be pervasive14,15, paired samples from any 
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